<SEC-DOCUMENT>0001104659-26-093042.txt : 20260810
<SEC-HEADER>0001104659-26-093042.hdr.sgml : 20260810
<ACCEPTANCE-DATETIME>20260810075004
ACCESSION NUMBER:		0001104659-26-093042
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20260809
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260810
DATE AS OF CHANGE:		20260810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Replimune Group, Inc.
		CENTRAL INDEX KEY:			0001737953
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				822082553
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38596
		FILM NUMBER:		261256257

	BUSINESS ADDRESS:	
		STREET 1:		500 UNICORN PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		(781) 222-9600

	MAIL ADDRESS:	
		STREET 1:		500 UNICORN PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2622673d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:repl="http://replimune.com/20260809">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_repl_replimune.com_20260809 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20260809_20260809 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001737953 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000004" name="dei:EntityCentralIndexKey">0001737953</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="repl-20260809.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-08-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001737953</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-08-09</xbrli:startDate>
        <xbrli:endDate>2026-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20260809__20260809_zQtqryMQHV38"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported):&#160; <b><span id="xdx_908_edei--DocumentPeriodEndDate_c20260809__20260809_zOR9yKf0nAa9"><ix:nonNumeric contextRef="AsOf2026-08-09" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">August 9, 2026</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityRegistrantName_c20260809__20260809_z0HW7fU7OS73"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000011" name="dei:EntityRegistrantName">REPLIMUNE GROUP, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20260809__20260809_zws1tgF9DTu6"><ix:nonNumeric contextRef="AsOf2026-08-09" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityFileNumber_c20260809__20260809_zBnErX30I6K3"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000013" name="dei:EntityFileNumber">001-38596</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20260809__20260809_zWi4jjlWBRPg"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000014" name="dei:EntityTaxIdentificationNumber">82-2082553</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission<br/>
File Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer<br/>
Identification Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_903_edei--EntityAddressAddressLine1_c20260809__20260809_zYyNmIeuknXf"><b><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000015" name="dei:EntityAddressAddressLine1">500
Unicorn Park Drive</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityAddressAddressLine2_c20260809__20260809_z6uOJuSWFt03"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 303</ix:nonNumeric></span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20260809__20260809_zFsVEz6iQ63a"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000017" name="dei:EntityAddressCityOrTown">Woburn</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20260809__20260809_zCTLK6gbEQs1"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000018" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20260809__20260809_z5EyWG4JEeZ4"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000019" name="dei:EntityAddressPostalZipCode">01801</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Address of principal executive offices, including Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_90C_edei--CityAreaCode_c20260809__20260809_zhtXg0Fektfk"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000020" name="dei:CityAreaCode">781</ix:nonNumeric></span>) <span id="xdx_90A_edei--LocalPhoneNumber_c20260809__20260809_z75UaWSbGA72"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000021" name="dei:LocalPhoneNumber">222-9600</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 3%">&#160;</td>
<td style="width: 3%; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90C_edei--WrittenCommunications_c20260809__20260809_z2ArrFf2z867"><ix:nonNumeric contextRef="AsOf2026-08-09" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: left; width: 94%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR
                                                                                                                         230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 3%">&#160;</td>
<td style="width: 3%; text-align: left"><span style="font-family: Wingdings"><span id="xdx_903_edei--SolicitingMaterial_c20260809__20260809_zQomUP6wZSji"><ix:nonNumeric contextRef="AsOf2026-08-09" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: left; width: 94%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                                                                                                                         240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 3%">&#160;</td>
<td style="width: 3%; text-align: left"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementTenderOffer_c20260809__20260809_zF1SEJxReWni"><ix:nonNumeric contextRef="AsOf2026-08-09" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: left; width: 94%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
                                                                                                                         240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 3%">&#160;</td>
<td style="width: 3%; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20260809__20260809_zSfjvq0420p4"><ix:nonNumeric contextRef="AsOf2026-08-09" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: left; width: 94%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
                                                                                                                         240.13e-4(c))<span style="font-family: Wingdings"></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Title of each class</span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading<br/>
Symbol(s)</span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span id="xdx_902_edei--Security12bTitle_c20260809__20260809_zvohtbOllsYi"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--TradingSymbol_c20260809__20260809_zEFV9I0Qydt3"><ix:nonNumeric contextRef="AsOf2026-08-09" id="Fact000027" name="dei:TradingSymbol">REPL</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--SecurityExchangeName_c20260809__20260809_zNYuW5qBvIC9"><ix:nonNumeric contextRef="AsOf2026-08-09" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span><br/>
(Nasdaq Global Select Market)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this
chapter). Emerging growth company <span style="font-family: Wingdings"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20260809__20260809_zzJuzWiE4wOa"><ix:nonNumeric contextRef="AsOf2026-08-09" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August&#160;9, 2026, Replimune
Group,&#160;Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Leerink
Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;) (each, an &#8220;Underwriter&#8221;
and, collectively, the &#8220;Underwriters&#8221;), relating to the issuance and sale of an aggregate of 9,701,490 shares of the Company&#8217;s
common stock (the &#8220;Shares&#8221;) and pre-funded warrants to purchase 2,736,340 shares of the Company&#8217;s common stock (the
&#8220;Pre-Funded Warrants&#8221;) to the Underwriters (the &#8220;Offering&#8221;). The Shares will be sold at the offering price of
$12.06 per share and the Pre-Funded Warrants will be sold at an offering price of $12.0599 per Pre-Funded Warrant, which equals the per
share offering price for the Shares less the $0.0001 exercise price for each such Pre-Funded Warrant. The Underwriting Agreement contains
customary representations and warranties, conditions to closing, market standoff provisions, termination provisions and indemnification
obligations, including for liabilities under the Securities Act of 1933, as amended. The representations, warranties and covenants contained
in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, and were solely for the benefit
of the parties to the Underwriting Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Pre-Funded Warrants are
exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together
with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&#8217;s common stock outstanding immediately
after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of 9.99%
by providing at least 61 days&#8217; prior notice to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company estimates
that net proceeds from the Offering will be approximately $140.5 million, after deducting underwriting discounts and commissions and
estimated Offering expenses payable by the Company. Delivery of the Shares and the Pre-Funded Warrants is expected to be made on or
about August&#160;11, 2026, subject to customary closing conditions. The Offering is being made pursuant to the Registration
Statement on Form&#160;S-3 (Registration No.&#160;333-287536) filed with the Securities and Exchange Commission (the
&#8220;Commission&#8221;) on May&#160;23, 2025, as amended by Amendment No.&#160;1 to the Registration Statement on Form&#160;S-3
filed on November&#160;6, 2025 (as so amended, the &#8220;Shelf Registration Statement&#8221;), pursuant to the Securities Act
of 1933, as amended (the &#8220;Securities Act&#8221;).</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Underwriting Agreement
and the form of Pre-Funded Warrant are filed as Exhibits 1.1 and 4.1 to this Current Report on Form&#160;8-K, respectively and the foregoing
description of the terms of the Underwriting Agreement and the Pre-Funded Warrants are qualified in their entirety by reference to such
exhibit. A copy of the opinion of Morgan, Lewis&#160;&amp; Bockius LLP relating to the legality of the issuance and sale of the Shares
and Pre-Funded Warrants in the Offering is filed with this Current Report on Form&#160;8-K as Exhibit&#160;5.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August&#160;10, 2026, the
Company issued a press release announcing the pricing of the Offering. A copy of this press release is attached as Exhibit&#160;99.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the disclosures on
this Current Report on Form&#160;8-K nor the exhibits hereto shall constitute an offer to sell or the solicitation of an offer to buy
the securities described herein and therein, nor shall there be any sale of such securities in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2622673d1_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2622673d1_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement dated August&#160;9, 2026</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2622673d1_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2622673d1_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Pre-Funded Warrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2622673d1_ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2622673d1_ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Morgan, Lewis&#160;&amp; Bockius LLP</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2622673d1_ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2622673d1_ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Morgan, Lewis&#160;&amp; Bockius LLP (included in Exhibit&#160;5.1)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2622673d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2622673d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated August&#160;10, 2026 announcing the pricing of the Offering</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover page&#160;interactive data file (formatted as Inline XBRL)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Current Report on Form&#160;8-K
contains forward looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E
of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements regarding the expected
net proceeds and the closing date of the Offering and other statements identified by words such as &#8220;could,&#8221; &#8220;expects,&#8221;
&#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221;
or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance,
and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to
differ materially from those contemplated in such forward-looking statements, including, but not limited to, the risks as may be detailed
from time to time in our Annual Reports on Form&#160;10-K and Quarterly Reports on Form&#160;10-Q and other reports we file with the SEC,
and in the final prospectus supplement and the accompanying prospectus related to the Offering. Our actual results could differ materially
from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof,
and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPLIMUNE GROUP,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August&#160;10, 2026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sushil Patel</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sushil Patel </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>







<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OkoXhfCupCSyCInodssxlnRHZre/R+ot25RoGBiGc75zhBiJnJa6QYbjvCxgj23XKIdQYo2M5ozeka3WKfhb4kVbx8q4/v2BGXkGPZOMpTx5obfetcUqhTCZRMlExhDKNJ7CbCOCr56RqXWFxmnVgDIV7Jg61ugUv4aEvXqSofbVVx2QrSaTQjQOB/kNMowkbOmuHsRXC0WRiWDUTyByplvnXYunQ/MlYdFg6+vsQP83+AABRkqD -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2622673d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT>EXECUTION
VERSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Replimune
Group,&nbsp;Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9,701,490 Shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pre-Funded Warrants to Purchase 2,736,340 Shares
of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Underwriting Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">August&nbsp;9, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leerink Partners LLC<BR>
J.P. Morgan Securities LLC<BR>
Cantor Fitzgerald&nbsp;&amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">As Representatives of the several <BR>
Underwriters
listed in Schedule I <BR>
hereto,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Leerink Partners LLC<BR>
1301 Avenue of the Americas, 5th Floor<BR>
New York, New York 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o J.P. Morgan Securities LLC<BR>
270 Park Avenue<BR>
New York, New York 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Cantor Fitzgerald&nbsp;&amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">110 East 59th Street, 6th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Replimune Group,&nbsp;Inc., a Delaware corporation
(the &ldquo;Company&rdquo;), proposes to issue and sell to the several underwriters listed in <U>Schedule </U>I hereto (the &ldquo;Underwriters&rdquo;),
for whom you are acting as representatives (the &ldquo;Representatives&rdquo;), an aggregate of 9,701,490 shares (the &ldquo;Underwritten
Shares&rdquo;) of common stock, par value $0.001 per share, of the Company (the &ldquo;Common Stock&rdquo;) and pre-funded warrants to
purchase an aggregate of 2,736,340 shares of Common Stock in a form to be mutually agreed by the Company and the Representatives (the
&ldquo;Warrants&rdquo;). The Underwritten Shares and the Warrants are herein referred to as the &ldquo;Securities&rdquo; or the &ldquo;Underwritten
Securities&rdquo;. The shares of Common Stock issuable upon exercise of the Warrants are herein referred to as the &ldquo;Warrant Shares&rdquo;.
The shares of Common Stock to be outstanding after giving effect to the sale of the Underwritten Shares and the exercise of the Warrants
are referred to herein as the &ldquo;Stock&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby confirms its agreement with
the several Underwriters concerning the purchase and sale of the Securities, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
Statement</U>. The Company has prepared and filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) under the
Securities Act of 1933, as amended, and the rules&nbsp;and regulations of the Commission thereunder (collectively, the &ldquo;Securities
Act&rdquo;), a registration statement on Form&nbsp;S-3 (File No.&nbsp;333-287536), including a prospectus, relating to the Underwritten
Shares, the Warrants and the Warrant Shares, filed with the Commission on May&nbsp;23, 2025 and amended by Amendment No.&nbsp;1 filed
on November&nbsp;6, 2025, which became effective 20 days following the filing of Amendment No.&nbsp;1 pursuant to Rule&nbsp;473(b)&nbsp;under
the Securities Act. Such registration statement, as amended at the time it became effective, including the information, if any, deemed
pursuant to Rule&nbsp;430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness
(&ldquo;Rule&nbsp;430 Information&rdquo;), is referred to herein as the &ldquo;Registration Statement&rdquo;; and as used herein, the
term &ldquo;Prospectus&rdquo; means the prospectus included in the Registration Statement, as supplemented by the final prospectus supplement
relating to the Securities, in the form first used (or made available upon request of purchasers pursuant to Rule&nbsp;173 under the Securities
Act) in connection with confirmation of sales of the Securities. If the Company has filed an abbreviated registration statement pursuant
to Rule&nbsp;462(b)&nbsp;under the Securities Act (the &ldquo;Rule&nbsp;462 Registration Statement&rdquo;), then any reference herein
to the term &ldquo;Registration Statement&rdquo; shall be deemed to include such Rule&nbsp;462 Registration Statement. Any reference in
this underwriting agreement (this &ldquo;Agreement&rdquo;) to the Registration Statement or the Prospectus shall be deemed to refer to
and include the documents incorporated by reference therein pursuant to Item 12 of Form&nbsp;S-3 under the Securities Act, as of the effective
date of the Registration Statement or the date of the Prospectus, as the case may be, and any reference to &ldquo;amend&rdquo;, &ldquo;amendment&rdquo;
or &ldquo;supplement&rdquo; with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include any documents
filed after such date under the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations of the Commission thereunder
(collectively, the &ldquo;Exchange Act&rdquo;) that are deemed to be incorporated by reference therein. Capitalized terms used but not
defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At or prior to the Applicable Time (as defined
below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the &ldquo;Pricing
Disclosure Package&rdquo;): the basic prospectus covering the securities described therein, which forms a part of and is included in the
Registration Statement, including any amendments by post-effective amendment or otherwise, in the form first used (or made available upon
request of purchasers pursuant to Rule&nbsp;173 under the Securities Act) in connection with the confirmation of sales of the Underwritten
Securities (including the documents incorporated by referenced therein pursuant to Item 12 of Form&nbsp;S-3 under the Securities Act)
and each &ldquo;free-writing prospectus&rdquo; (as defined pursuant to Rule&nbsp;405 under the Securities Act) listed on Annex A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Applicable Time&rdquo; means 8:30 P.M.,
New York City time, on August&nbsp;9, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Purchase
of the Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company agrees to issue and sell the Underwritten Securities to the several Underwriters, and each Underwriter, on the basis of the representations,
warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase
at a price per share of Common Stock of $11.3364 (the &ldquo;Share Purchase Price&rdquo;) from the Company the respective number of Underwritten
Shares set forth opposite such Underwriter&rsquo;s name in Schedule I hereto and to purchase from the Company Warrants in respect of
the respective number of Warrant Shares set forth opposite such Underwriter&rsquo;s name in Schedule I hereto at a price of $11.3363
per Warrant Share (the &ldquo;Warrant Purchase Price&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company understands that the Underwriters intend to make an offering of the Securities, and initially to offer the Securities on the terms
set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell the Securities
to or through any of their respective affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Payment
for the Securities shall be made by wire transfer in immediately available funds to the account specified by the Company to the Representatives
at the offices of Cravath, Swaine&nbsp;&amp; Moore LLP, Two Manhattan West, New York, New York 10001 at 10:00 A.M.&nbsp;New York City
time on August&nbsp;11, 2026, or at such other time or place on the same or such other date, not later than the fifth business day thereafter,
as the Representatives and the Company may agree upon in writing. The time and date of such payment for the Underwritten Securities is
referred to herein as the &ldquo;Closing Date&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payment for the Securities to be purchased on the
Closing Date shall be made against delivery to the Representatives for the respective accounts of the several Underwriters of the Securities
to be purchased on such date, with any transfer taxes payable in connection with the sale of such Securities duly paid by the Company.
Delivery of the Underwritten Shares shall be made through the facilities of The Depository Trust Company (&ldquo;DTC&rdquo;) unless the
Representatives shall otherwise instruct. The Warrants shall be delivered to the Representatives in definitive form, registered in such
names and in such denominations as the Representatives shall request in writing not later than the Closing Date. The Warrants will be
made available for inspection by the Representatives on the business day prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the foregoing, the Company and
the Representatives shall instruct purchasers of the Warrants in the offering to make payment for the Warrants on the Closing Date to
the Company by wire transfer in immediately available funds to the account specified by the Company at a purchase price of $12.0599 per
Warrant Share, in lieu of payment by the Underwriters for such Warrants, and the Company shall deliver such Warrants to such purchasers
on the Closing Date in definitive form against such payment, in lieu of the Company&rsquo;s obligation to deliver such Warrants to the
Underwriters&#894; <U>provided</U> that, upon receipt by the Company of payment for the Warrants, the Company shall promptly (but in no
event later than the Closing Date) pay $0.7236 per Warrant Share to the Underwriters by wire transfer in immediately available funds to
the account specified by the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event that the purchasers of the Warrants
in the offering fail to make payment to the Company for all or part of the Warrants on the Closing Date, the Representatives may elect,
by written notice to the Company, to receive shares of Common Stock in lieu of all or a portion of such Warrants to be delivered to the
Underwriters under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity of an arm&rsquo;s
length contractual counterparty to the Company with respect to the offering of Securities contemplated hereby (including in connection
with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other
person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal,
tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such
matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and
neither the Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto.
Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating
to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Representations
and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Reserved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Pricing
Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date will not, contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty
with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished
to the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being
understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof.
No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material
fact included in the Pricing Disclosure Package that is required to be included in the Prospectus has been omitted therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Issuer
Free Writing Prospectus. </I>Other than the Registration Statement and the Prospectus, the Company (including its agents and representatives,
other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not
prepare, make, use, authorize, approve or refer to any &ldquo;written communication&rdquo; (as defined in Rule&nbsp;405 under the Securities
Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company or its
agents and representatives (other than a communication referred to in clause (i)&nbsp;below), an &ldquo;Issuer Free Writing Prospectus&rdquo;)
other than (i)&nbsp;any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a)&nbsp;of the Securities Act or Rule&nbsp;134
under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications
approved in writing in advance by the Representatives. Each such Issuer Free Writing Prospectus complies in all material respects with
the Securities Act, has been or will be (within the time period specified in Rule&nbsp;433) filed in accordance with the Securities Act
(to the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure
Package, and, when taken together with such Issuer Free Writing Prospectus, did not, and as of the Closing Date will not, contain any
untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with
respect to any statements or omissions made in each such Issuer Free Writing Prospectus in reliance upon and in conformity with information
relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such
Issuer Free Writing Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of
the information described as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Reserved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Testing-the-Waters
Communications.</I> &ldquo;Testing-the-Waters Communication&rdquo; means any oral or written communication with potential investors undertaken
in reliance on either Section&nbsp;5(d)&nbsp;of, or Rule&nbsp;163B under, the Securities Act. The Company (i)&nbsp;has not alone engaged
in any Testing-the-Waters Communications and (ii)&nbsp;has not authorized anyone to engage in Testing-the-Waters Communications. &ldquo;Rule&nbsp;163
Communication&rdquo; means any offer made in reliance on Rule&nbsp;163 under the Securities Act by the Company as a well-known seasoned
issuer. The Company has not engaged in any Rule&nbsp;163 Communication, and no such Rule&nbsp;163 Communication, if any, has been made
other than in compliance with Rule&nbsp;163 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Registration
Statement and Prospectus.</I> The Registration Statement became effective pursuant to Section&nbsp;8(a)&nbsp;of the Securities Act upon
the expiration of 20 days following the filing of Amendment No.&nbsp;1 to the Registration Statement in compliance with Rule&nbsp;473(b)&nbsp;under
the Securities Act. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding
for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Securities
has been initiated or, to the best knowledge of the Company, threatened by the Commission; as of the applicable effective date of the
Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied
and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading;
and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date, the Prospectus will not contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty
with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished
to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus
and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists
of the information described as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Incorporated
Documents.</I> The documents incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such
documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference
in the Registration Statement, the Pricing Disclosure Package or the Prospectus, when such documents are filed with the Commission, will
conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Financial
Statements.</I> The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects
with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects
the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations
and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally
accepted accounting principles (&ldquo;GAAP&rdquo;) in the United States applied on a consistent basis throughout the periods covered
thereby, except unaudited financial statements, which are subject to normal year-end adjustments and do not contain certain footnotes
as permitted by the applicable rules&nbsp;of the Commission, and any supporting schedules included or incorporated by reference in the
Registration Statement present fairly in all material respects the information required to be stated therein; and the other financial
information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has
been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects
the information shown thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included or incorporated by reference
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any material change in the
capital stock (other than the issuance of shares of Common Stock (x)&nbsp;upon exercise or settlement of stock options, warrants or restricted
stock units described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration
Statement, the Pricing Disclosure Package and the Prospectus and (y)&nbsp;in accordance with the terms of that certain Sales Agreement,
dated as of August&nbsp;3, 2023, as amended by Amendment No.&nbsp;1 thereto, dated as of May&nbsp;16, 2024, Amendment No.&nbsp;2 thereto,
dated November&nbsp;25, 2024 and Amendment No.&nbsp;3 thereto, dated May&nbsp;22, 2025, by and between the Company and Leerink Partners
LLC), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared,
set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development that
would reasonably be expected to result in a prospective material adverse change, in or affecting the business, properties, management,
financial position, stockholders&rsquo; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole;
(ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary
course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct
or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its
subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a
whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance
or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise
disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Organization
and Good Standing.</I> The Company and each of its subsidiaries have been duly organized and are validly existing and in good standing
under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction
in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and
have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged,
except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate,
reasonably be expected to have a material adverse effect on the business, properties, management, financial position, stockholders&rsquo;
equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of
its obligations under this Agreement (a &ldquo;Material Adverse Effect&rdquo;). The Company does not own or control, directly or indirectly,
any corporation, association or other entity other than the subsidiaries listed in Exhibit&nbsp;21 to the Company&rsquo;s most recent
Annual Report on Form&nbsp;10-K filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Capitalization.</I>
The Company has an authorized capitalization as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus
under the heading &ldquo;Description of Capital Stock&rdquo;; all the outstanding shares of capital stock of the Company have been duly
and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights that
have not been duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure
Package and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights that have not been duly
waived or satisfied), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock
or other equity interests in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement
of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable
securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description
thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of
capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized
and issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and clear of any lien, charge,
encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Stock
Options. </I>With respect to the stock options (the &ldquo;Stock Options&rdquo;) granted pursuant to the stock-based compensation plans
of the Company (the &ldquo;Company Stock Plans&rdquo;), (i)&nbsp;each Stock Option intended to qualify as an &ldquo;incentive stock option&rdquo;
under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), so qualifies, (ii)&nbsp;except, in each
case, for any such matters as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, each
grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective
by all necessary corporate action, including, as applicable, approval by the Board of Directors of the Company (or a duly constituted
and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the
award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made
in accordance with the terms of the Company Stock Plans and all other applicable laws and regulatory rules&nbsp;or requirements and (iv)&nbsp;each
such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company
and disclosed in the Company&rsquo;s filings with the Commission in accordance with the Exchange Act and all other applicable laws. The
Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior
to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding
the Company or its subsidiaries or their results of operations or prospects. The descriptions of Company Stock Plans and the options or
other rights granted thereunder set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus accurately
and fairly present the information required to be shown with respect to such Company Stock Plans and the options or other rights granted
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Due
Authorization.</I> The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations
hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and
the consummation by it of the transactions contemplated hereby has been duly and validly taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Underwriting
Agreement. </I> This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>The
Securities. </I>(i)&nbsp;The Underwritten Shares to be issued and sold by the Company hereunder have been duly authorized by the Company
and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable
and will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and
the Prospectus; (ii)&nbsp;the Warrants have been duly authorized by the Company and, when executed and delivered by the Company in accordance
with this Agreement, will constitute valid and legally binding agreements of the Company enforceable against the Company in accordance
with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors&rsquo;
rights generally or by equitable principles relating to enforceability; (iii)&nbsp;the Warrant Shares to be issued by the Company upon
exercise of the Warrants, as provided therein, have been duly and validly authorized and, when issued and delivered upon exercise as provided
under the Warrant, will be duly and validly issued, fully paid and non-assessable and will conform in all material respects to the descriptions
thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and (iv)&nbsp;the issuance of the Securities
and the Warrant Shares is not subject to any preemptive, rights of first refusal or similar rights that have not been duly waived or satisfied.
When issued and delivered by the Company against payment therefor pursuant to this Agreement, the Underwriters will acquire good, marketable
and valid title to their respective Underwritten Shares, free and clear of all pledges, liens, security interests, charges, claims or
encumbrances. When issued and delivered by the Company pursuant to the Warrants, the holders thereof will acquire good, marketable and
valid title to the Warrant Shares, free and clear of all pledges, liens, security interests, charges, claims or encumbrances. The issuance
and sale of the Securities as contemplated hereby will not cause any holder of any share capital, securities convertible into or exchangeable
or exercisable for share capital or options, warrants or other rights to purchase share capital or any other securities of the Company
to have any right to acquire any preferred shares of the Company. There are no restrictions upon the voting or transfer of the Stock under
the Company&rsquo;s amended and restated certificate of incorporation or amended and restated bylaws or any agreement or other instrument
to which the Company is a party or otherwise filed as an exhibit to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Description
of the Underwriting Agreement.</I> This Agreement conforms in all material respects to the description thereof contained in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Violation or Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or by-laws or similar
organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute
such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of
trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company
or any of its subsidiaries is bound or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in
violation of any applicable law or statute or any judgment, order, rule&nbsp;or regulation of any court or arbitrator or governmental
or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii)&nbsp;above, for any such default or violation that would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Conflicts. </I>The execution, delivery and performance by the Company of this Agreement and the Warrants by the Company, the issuance
and sale of the Securities and the Warrant Shares by the Company and the consummation of the transactions contemplated by this Agreement
and in the Warrants (with or without notice or lapse of time or both) will not (i)&nbsp;conflict with or result in a breach or violation
of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result
in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or any of its subsidiaries
pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the Company
or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or by-laws or similar organizational
documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order,
rule&nbsp;or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and
(iii)&nbsp;above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Consents Required.</I> No consent, approval, authorization, order, license, registration or qualification of or with any court or arbitrator
or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the
issuance and sale of the Securities and the consummation of the transactions contemplated by this Agreement, except for the registration
of the Securities under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as
may be required by the Financial Industry Regulatory Authority,&nbsp;Inc. and under applicable state securities laws in connection with
the purchase and distribution of the Securities by the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Legal
Proceedings.</I> Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no legal,
governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&ldquo;Actions&rdquo;)
pending to which the Company or any of its subsidiaries is or may be a party or to which any property of the Company or any of its subsidiaries
is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would
reasonably be expected to have a Material Adverse Effect; to the best knowledge of the Company, no such Actions are threatened or contemplated
by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions that are required
under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not
so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations
or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described
in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration
Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Independent
Accountants</I>. PricewaterhouseCoopers LLP, whose report on the consolidated financial statements of the Company is filed with the Commission
as part of the Company&rsquo;s most recent Annual Report on Form&nbsp;10-K filed with the Commission and incorporated by reference in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, is an independent registered public accounting firm with
respect to the Company and its subsidiaries within the applicable rules&nbsp;and regulations adopted by the Commission and the Public
Company Accounting Oversight Board (United States) and as required by the Securities Act. PricewaterhouseCoopers LLP has not been engaged
by the Company to perform any &ldquo;prohibited activities&rdquo; or provided to the Company any &ldquo;non-audit services&rdquo; (as
defined in Section&nbsp;10A of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Title
to Real and Personal Property</I>. The Company and its subsidiaries have good and marketable title in fee simple (in the case of real
property) to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the businesses
of the Company and its subsidiaries taken as a whole, in each case free and clear of all liens, encumbrances, claims and defects and imperfections
of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company
and its subsidiaries or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Intellectual
Property.</I> The Company and its subsidiaries own or license rights to use inventions, patent rights, trademarks, service marks, trade
names, trade dress, domain names, copyrights, licenses, know-how, trade secrets and other unpatented and/or unpatentable proprietary or
confidential information, systems or procedures (including all registrations and applications for registration of, and all goodwill associated
with, any of the foregoing, as applicable) (collectively, &ldquo;Intellectual Property&rdquo;) described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus as being owned by or licensed to the Company and its subsidiaries, and, to the best
knowledge of the Company, all other Intellectual Property used in or reasonably necessary for the conduct of their business as currently
conducted and as proposed to be conducted in the Registration Statement, Pricing Disclosure Package or the Prospectus, and, to the best
knowledge of the Company, such Intellectual Property rights are valid and enforceable. To the best knowledge of the Company, the conduct
of the business of the Company and its subsidiaries does not, and the proposed conduct of such business as disclosed in the Registration
Statement, Pricing Disclosure Package or the Prospectus will not, infringe, misappropriate or otherwise violate any Intellectual Property
rights of any others. Except as described in the Registration Statement, Pricing Disclosure Package or the Prospectus, there is no pending
or, to the Company&rsquo;s best knowledge, threatened action, suit, proceeding or claim by any others (i)&nbsp;that the Company or any
of its subsidiaries infringes, misappropriates or otherwise violates the Intellectual Property of others, or (ii)&nbsp;challenging the
validity, enforceability, scope or ownership of any Intellectual Property owned by or licensed to the Company or any of its subsidiaries
or their rights therein. To the best knowledge of the Company, no third party has infringed, misappropriated or otherwise violated any
Intellectual Property owned by or exclusively licensed to the Company or any of its subsidiaries. To the best knowledge of the Company,
none of the Intellectual Property used by the Company or any of its subsidiaries in the conduct of its business has been obtained or is
being used by the Company or any of its subsidiaries in material violation of any contractual obligation binding on the Company or any
of its subsidiaries. Except as set forth in the Registration Statement, Pricing Disclosure Package or the Prospectus, the Intellectual
Property owned by the Company and its subsidiaries is solely owned by the Company or its subsidiaries free and clear of any liens or encumbrances.
Neither the Company nor any of its subsidiaries is subject to any judgment, order, writ, injunction or decree of any court or any federal,
state, local, foreign or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, or
any arbitrator, nor has it entered into or is a party to any agreement made in settlement of any pending or threatened litigation, which
materially restricts or impairs its use of any Intellectual Property. The Company and its subsidiaries have taken commercially reasonable
steps, in accordance with normal industry practice for a company of like size and resources, to maintain the confidentiality of all Intellectual
Property the value of which to the Company or any of its subsidiaries is contingent upon maintaining the confidentiality thereof, and
neither the Company nor any of its subsidiaries is aware of any material disclosure of such Intellectual Property other than to employees,
representatives, independent contractors, collaborators, licensors, licensees, agents and advisors of the Company and its subsidiaries,
all of whom are bound by written obligations to maintain the confidentiality thereof. All founders, officers and other employees involved
in the development of Intellectual Property for the Company and its subsidiaries have signed confidentiality and invention assignment
agreements or similar agreements for the transfer, assignment, and/or licensing of Intellectual Property with the Company and its subsidiaries
pursuant to which the Company and its subsidiaries either (i)&nbsp;have obtained ownership of and are the exclusive owners of, or (ii)&nbsp;have
a valid and unrestricted right to exploit, sufficient for the conduct of their business, such Intellectual Property. No founder, officer
or, to the Company&rsquo;s best knowledge, other employee of the Company is in or has been in material violation of any term of any employment
contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, non-disclosure
agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such founder, officer
or employee&rsquo;s relationship or activities with the Company or its subsidiaries, or otherwise relates to rights in the Intellectual
Property owned or purported to be owned by or licensed to the Company or its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Patents
and Patent Applications</I>. All patents and patent applications owned by, co-owned by, or exclusively licensed to the Company or under
which the Company has rights (&ldquo;Patents and Patent Applications&rdquo;) have been duly and properly filed and are being diligently
prosecuted and maintained; the parties prosecuting, or that have prosecuted, the Patents and Patent Applications have complied with their
duty of candor and disclosure to the applicable patent office in connection with such Patents and Patent Applications; and to the Company&rsquo;s
best knowledge after due inquiry, there is no prior art that has rendered or may render any Patent or Patent Application invalid or unpatentable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on
the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries,
on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that
is not so described in such documents and in the Pricing Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Investment
Company Act</I>. The Company is not and, after giving effect to the offering and sale of the Securities and the application of the proceeds
thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register
as an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment company&rdquo; within the meaning
of the Investment Company Act of 1940, as amended, and the rules&nbsp;and regulations of the Commission thereunder (collectively, the
&ldquo;Investment Company Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Taxes.</I>
Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its subsidiaries
have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof
except for taxes being contested in good faith and for which reserves in accordance with GAAP in the United States have been taken; and
except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no tax
deficiency that has been, or would reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their
respective properties or assets that would reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Licenses
and Permits.</I> Except as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
and its subsidiaries possess all licenses, sub-licenses, certificates, permits and other authorizations issued by, and have made all declarations
and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership
or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement,
the Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect; and except as described in each of the Registration Statement,
the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation
or modification of any such license, sub-license, certificate, permit or authorization or has any reason to believe that any such license,
sub-license, certificate, permit or authorization will not be renewed in the ordinary course, except where the failure to pay or file
or where such revocation, modification or nonrenewal would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the best
knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by,
or dispute with, the employees of any of its or its subsidiaries&rsquo; principal suppliers, contractors or customers, except as would
not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries is a party to any collective
bargaining agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Certain
Environmental Matters</I>. (i)&nbsp;The Company and its subsidiaries (A)&nbsp;are in compliance with all applicable federal, state, local
and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable
requirements relating to pollution or the protection of human health or safety, the environment or natural resources (collectively, &ldquo;Environmental
Laws&rdquo;); (B)&nbsp;have obtained and are and have been in compliance with all permits, licenses, certificates or other authorizations
or approvals required under any Environmental Laws to conduct their respective businesses; (C)&nbsp;are not a party to any order, decree
or agreement that imposes any obligation or liability under any Environmental Law; and (D)&nbsp;have not received notice of any actual
or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including
for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants,
and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no
costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each
of (i)&nbsp;and (ii)&nbsp;above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect; and (iii)&nbsp;except as described in each of the Pricing Disclosure Package and the Prospectus, (A)&nbsp;there
is no proceeding that is pending, or, to the Company&rsquo;s best knowledge, contemplated, against the Company or any of its subsidiaries
under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which it is reasonably
believed no monetary sanctions of $300,000 or more will be imposed, (B)&nbsp;the Company and its subsidiaries are not aware of any facts
or issues regarding compliance with Environmental Laws that would reasonably be expected to have a material effect on the capital expenditures,
earnings or competitive position of the Company and its subsidiaries, and (C)&nbsp;none of the Company or its subsidiaries anticipates
material capital expenditures relating to any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Compliance
with ERISA</I>. (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee Retirement Income Security
Act of 1974, as amended (&ldquo;ERISA&rdquo;), for which the Company or any member of its &ldquo;Controlled Group&rdquo; (defined as any
entity, whether or not incorporated, that is under common control with the Company within the meaning of Section&nbsp;4001(a)(14) of ERISA
or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m)&nbsp;or (o)&nbsp;of the Code)
would have any liability (each, a &ldquo;Plan&rdquo;) has been maintained in compliance with its terms and the requirements of any applicable
statutes, orders, rules&nbsp;and regulations, including but not limited to ERISA and the Code, in all material respects; (ii)&nbsp;no
prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to
any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;no Plan is or ever has been
subject to Section&nbsp;302 of ERISA, Title IV of ERISA or Section&nbsp;412 of the Code and no Plan is a &ldquo;multiemployer plan&rdquo;
within the meaning of Section&nbsp;4001(a)(3)&nbsp;of ERISA; (iv)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a)&nbsp;of
the Code is subject to a favorable determination letter or advisory opinion, as applicable, from the IRS and no event has occurred and
no condition exists, whether by action or by failure to act, that, to the Company&rsquo;s best knowledge, is reasonably likely to result
in the revocation of any such determination or opinion, as applicable, and (v)&nbsp;none of the following events has occurred or, to the
Company&rsquo;s best knowledge, is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required
to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled
Group affiliates compared to the amount of such contributions made in the Company&rsquo;s and its Controlled Group affiliates&rsquo; most
recently completed fiscal year; or (B)&nbsp;a material increase in the Company and its subsidiaries&rsquo; &ldquo;accumulated post-retirement
benefit obligations&rdquo; (within the meaning of Accounting Standards Codification Topic 715-60) compared to the amount of such obligations
in the Company and its subsidiaries&rsquo; most recently completed fiscal year, except in each case with respect to the events or conditions
set forth in (i)&nbsp;through (v)&nbsp;hereof, as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Disclosure
Controls</I>. The Company and its subsidiaries maintain an effective system of &ldquo;disclosure controls and procedures&rdquo; (as defined
in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to
ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms, including controls
and procedures designed to ensure that such information is accumulated and communicated to the Company&rsquo;s management as appropriate
to allow timely decisions regarding required disclosure. Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls
and procedures as required by Rule&nbsp;13a-15 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Accounting
Controls.</I> The Company and its subsidiaries maintain systems of &ldquo;internal control over financial reporting&rdquo; (as defined
in Rule&nbsp;13a-15(f)&nbsp;of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under
the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable
assurance that (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability;
(iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (iv)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the
Registration Statement, the Pricing Disclosure Package and the Prospectus fairly presents the information called for in all material respects
and is prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto. Except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the Company&rsquo;s internal controls.
The Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant
deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected
or are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information;
and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s
internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Insurance.
</I>The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including
business interruption insurance and policies covering the Company and its subsidiaries for product liability claims and clinical trial
liability claims, which insurance is in amounts and insures against such losses and risks as are adequate to protect the Company and its
subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any
insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue
such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Cyber
Security; Data Protection. </I>The Company and its subsidiaries&rsquo; information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications, and databases (collectively, &ldquo;IT Systems&rdquo;) are adequate for, and operate
and perform in all material respects as required in connection with the operations of the business of the Company and its subsidiaries
as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants.
The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&ldquo;Personal Data&rdquo;))
used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to
same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents
under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with
all applicable laws or statutes and all applicable judgments, orders, rules&nbsp;and regulations of any court or arbitrator or governmental
or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal
Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. The Company
and its subsidiaries are in compliance with the European Union General Data Protection Regulation and the United Kingdom General Data
Protection Regulation (and all other applicable laws and regulations with respect to Personal Data for which any non-compliance with the
same would be reasonably likely to create a material liability).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Unlawful Payments.</I> Neither the Company nor any of its subsidiaries nor any director, officer or employee of the Company or any of
its subsidiaries nor, to the best knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of
the Company or any of its subsidiaries has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other
unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of
any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned
or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of
the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any
provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention
on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act
2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested
or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence
payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce,
and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery
and anti-corruption laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Compliance
with Anti-Money Laundering Laws</I>. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts
business, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or
enforced by any governmental agency (collectively, the &ldquo;Anti-Money Laundering Laws&rdquo;), and no action, suit or proceeding by
or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with
respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the best
knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries
is currently the subject or the target of any sanctions administered or enforced by the U.S. government (including, without limitation,
the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;OFAC&rdquo;) or the U.S. Department of State and including,
without limitation, the designation as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;), the United Nations
Security Council (&ldquo;UNSC&rdquo;), the European Union, His Majesty&rsquo;s Treasury (&ldquo;HMT&rdquo;) or other relevant sanctions
authority (collectively, &ldquo;Sanctions&rdquo;), nor is the Company or any of its subsidiaries located, organized or resident in a country
or territory that is the subject or target of Sanctions, including, without limitation, Cuba,&nbsp;Iran, North Korea, the Crimea, Zaporizhzhia
and Kherson regions of Ukraine and the so-called Donetsk People&rsquo;s Republic and Luhansk People&rsquo;s Republic regions of Ukraine
(each, a &ldquo;Sanctioned Country&rdquo;); and the Company will not directly or indirectly use the proceeds of the offering of the Securities
hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity
(i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the
subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in
any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter,
advisor, investor or otherwise) of Sanctions. Since their respective inceptions, the Company and its subsidiaries have not knowingly engaged
in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is
or was the subject or the target of Sanctions or with any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(mm)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Outbound
Investment Security Program</I>. Neither the Company nor any of its subsidiaries is a &ldquo;covered foreign person&rdquo;, as that term
is defined in 31 C.F.R. &sect; 850.209. Neither the Company nor any of its subsidiaries currently engages, or has plans to engage, directly
or indirectly, in a &ldquo;covered activity&rdquo;, as that term is defined in 31 C.F.R. &sect; 850.208 (&ldquo;Covered Activity&rdquo;).
The Company does not have any joint ventures that engage in or plan to engage in any Covered Activity. The Company also does not, directly
or indirectly, hold a board seat on, have a voting or equity interest in, or have any contractual power to direct or cause the direction
of the management or policies of any person or persons that engages or plans to engage in any Covered Activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(nn)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or
other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on
such subsidiary&rsquo;s capital stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary
from the Company or from transferring any of such subsidiary&rsquo;s properties or assets to the Company or any other subsidiary of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(oo)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Broker&rsquo;s Fees.</I> Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any
person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission,
finder&rsquo;s fee or like payment in connection with the offering and sale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(pp)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Registration Rights</I>. No person has the right to require the Company or any of its subsidiaries to register any securities for sale
under the Securities Act by reason of the filing of the Registration Statement or the Prospectus with the Commission or the issuance and
sale of the Securities, other than rights that have been validly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(qq)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Stabilization.</I> Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that would
reasonably be expected to cause or result in any stabilization or manipulation of the price of any Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(rr)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Margin
Rules</I>. Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the Company as described
in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board
of Governors of the Federal Reserve System or any other regulation of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ss)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Forward-Looking
Statements.</I> No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus
has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. No such statement was made with
the knowledge of a director or executive officer of the Company that was false or misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(tt)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Statistical
and Market Data.</I> Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and
market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the
Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(uu)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Sarbanes-Oxley
Act</I>. There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or officers, in their capacities
as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules&nbsp;and regulations promulgated in
connection therewith (the &ldquo;Sarbanes-Oxley Act&rdquo;), including Section&nbsp;402 related to loans and Sections 302 and 906 related
to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Status
under the Securities Act</I>. At the time of filing the Registration Statement, at the earliest time thereafter that the Company or any
offering participant made a <I>bona fide</I> offer (within the meaning of Rule&nbsp;164(h)(2)&nbsp;under the Securities Act) of the Securities
and at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule&nbsp;405 under the Securities
Act, without taking account of any determination by the Commission pursuant to Rule&nbsp;405 that it is not necessary that the Company
be considered an ineligible issuer. The Company has paid the registration fee for this offering pursuant to the applicable rules&nbsp;under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ww)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities, convertible securities or preferred stock issued or
guaranteed by the Company or any of its subsidiaries that are rated by a &ldquo;nationally recognized statistical rating organization&rdquo;,
as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xx)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Indebtedness</I>. Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the
Company and its subsidiaries have no outstanding indebtedness for borrowed money.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(yy)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Contract Terminations</I>.&nbsp;The Company has not sent or received any communication regarding termination of, or intent not to renew,
any of the contracts or agreements described in the Prospectus, any Issuer Free Writing Prospectus, or referred to or described in, or
filed as an exhibit to, the Registration Statement, and no such termination or non-renewal has been threatened by the Company or, to the
Company&rsquo;s best knowledge, any other party to any such contract or agreement, which threat of termination or non-renewal has not
been rescinded as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(zz)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Preclinical
and Clinical Trials</I>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus: (i)&nbsp;the
preclinical and clinical studies and trials conducted by or, to the best knowledge of the Company after due inquiry, that were conducted
on behalf of or sponsored by the Company or its subsidiaries, or in which the Company or its subsidiaries have participated (collectively
&ldquo;Company Trials&rdquo;), in each case including the Company&rsquo;s studies and trials that are described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, or the results of which are referred to in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, as applicable, were, and if still pending are, being conducted in all material respects in accordance
with all applicable standard medical and scientific research standards and procedures and all applicable statutes and all applicable rules&nbsp;and
regulations of the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;), the Department of Health and Human Services and comparable regulatory
agencies outside of the United States to which they are subject, including the European Medicines Agency (collectively, the &ldquo;Regulatory
Authorities&rdquo;), and applicable current Good Clinical Practice and Good Laboratory Practice requirements as detailed in applicable
statutes, rules&nbsp;and regulations of an applicable Regulatory Authority; (ii)&nbsp;the descriptions in the Registration Statement,
the Pricing Disclosure Package and the Prospectus of the Company Trials, including the results of the Company Trials, are accurate and
complete descriptions in all material respects and fairly present the data derived therefrom; (iii)&nbsp;the Company has no knowledge
of any other studies or trials not described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the results
of which are inconsistent with or call into question the results of the Company Trials described or referred to in the Registration Statement,
the Pricing Disclosure Package and the Prospectus; (iv)&nbsp;neither the Company nor any of its subsidiaries, nor, to the Company&rsquo;s
best knowledge after due inquiry, any of its collaboration partners, have received any written notices, written correspondence or other
written communications from the Regulatory Authorities or any other governmental agency requiring or threatening the termination, material
modification or suspension of any Company Trial that is described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, other
than ordinary course communications with respect to modifications in connection with the design and implementation of such Company Trials,
and, to the Company&rsquo;s best knowledge after due inquiry, there are no reasonable grounds for the same; (v)&nbsp;to the Company&rsquo;s
best knowledge after due inquiry, the Company has obtained (or caused to be obtained) informed consent by or on behalf of each human subject
who participated in a Company Trial; (vi)&nbsp;in using or disclosing patient information received by the Company in connection with the
Company Trials, the Company has complied in all material respects with all applicable laws and regulatory rules&nbsp;or requirements;
and (vii)&nbsp;to the Company&rsquo;s best knowledge after due inquiry, none of the Company Trials involved any investigator who has been
disqualified as a clinical investigator by any Regulatory Authority or has been found by any Regulatory Authority to have engaged in scientific
misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aaa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Product
Candidates</I>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company: (i)&nbsp;has
operated and currently operates its business in compliance in all material respects with applicable provisions of the Health Care Laws
(as defined below) applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage,
import, export or disposal of any of the Company&rsquo;s product candidates; (ii)&nbsp;has not received any FDA Form&nbsp;483, written
notice of adverse finding, warning letter, untitled letter or other written correspondence or written notice from any court or arbitrator,
Regulatory Authority or other governmental or regulatory authority alleging or asserting non-compliance with (A)&nbsp;any Health Care
Laws or (B)&nbsp;any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments
thereto required by any such Health Care Laws (&ldquo;Regulatory Authorizations&rdquo;); (iii)&nbsp;possesses all Regulatory Authorizations
required to conduct its business as currently conducted and such Regulatory Authorizations are valid and in full force and effect and
the Company is not in violation, in any material respect, of any term of any such Regulatory Authorizations; (iv)&nbsp;has not received
written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any of the
Regulatory Authorities or any other third party alleging that any product operation or activity is in material violation of any Health
Care Laws or Regulatory Authorizations and has no knowledge that any of the Regulatory Authorities or any other third party is considering
any such claim, litigation, arbitration, action, suit, investigation or proceeding that would, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect; (v)&nbsp;has not received written notice that any of the Regulatory Authorities has taken,
is taking or intends to take action to limit, suspend, modify or revoke any Regulatory Authorizations and has no knowledge that any of
the Regulatory Authorities is considering such action that would, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect; (vi)&nbsp;is not a party to or does not have any ongoing reporting obligations pursuant to any corporate integrity agreements,
deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements
with or imposed by any Regulatory Authority; and (vii)(A)&nbsp;has not, nor have any of its directors, officers or, to the Company&rsquo;s
best knowledge, employees, been excluded, suspended or debarred by a Regulatory Authority from participation in any government health
care program or human clinical research or (B), to the best knowledge of the Company after due inquiry, is not, and none of its directors,
officers or employees is, subject to a governmental inquiry, investigation, proceeding, or other similar action that would reasonably
be expected to result in debarment, suspension, or exclusion by a Regulatory Authority. For purposes of this Agreement, &ldquo;Health
Care Laws&rdquo; means, to the extent applicable to the Company, all health care laws applicable to the Company, including, but not limited
to: Title XVIII of the Social Security Act, 42 U.S.C. &sect;&sect; 1395-1395hhh (the Medicare statute); Title XIX of the Social Security
Act, 42 U.S.C. &sect;&sect; 1396-1396v (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. &sect; 1320a-7b(b); the civil
False Claims Act, 31 U.S.C. &sect;&sect; 3729 et seq.; the criminal False Claims Act 42 U.S.C. &sect;&nbsp;1320a-7b(a); any criminal laws
relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287 and the health care fraud criminal
provisions under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &sect;&sect; 1320d et seq.; the Physician
Payments Sunshine Act, 42 U.S.C. &sect; 1320a-7h; the Exclusion Laws, 42 U.S.C. &sect; 1320a-7; the Federal Food, Drug, and Cosmetic Act,
21 U.S.C. &sect;&sect; 301 et seq.; the Public Health Service Act, 42 U.S.C. &sect;&sect; 201 et seq.; the regulations promulgated pursuant
to such laws; and any similar federal, state and local laws and regulations, in each case of the foregoing laws and regulations, as amended
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bbb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Manufacturing</I>.
To the Company&rsquo;s best knowledge, the contract manufacturing facilities and GMP operations of its suppliers are operated in compliance
in all material respects with all applicable statutes, rules&nbsp;and regulations of the Regulatory Authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ccc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Regulatory
Filings</I>. The Company has not failed to file with the Regulatory Authorities any required filing, declaration, listing, registration,
report or submission with respect to the Company&rsquo;s product candidates that are described or referred to in the Registration Statement,
the Pricing Disclosure Package and the Prospectus; all such filings, declarations, reports or submissions were in material compliance
with the applicable Health Care Laws when filed; and no material deficiencies regarding compliance with applicable law have been asserted
by any Regulatory Authority with respect to any such filings, declarations, reports or submissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ddd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Exchange
Act Requirements; Stock Exchange Listing</I>. The Company is subject to and in compliance in all material respects with the reporting
requirements of Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of the Exchange Act. The Stock is registered pursuant to Section&nbsp;12(b)&nbsp;of
the Exchange Act and is listed on the Nasdaq Global Select Market (the &ldquo;Nasdaq Market&rdquo;), and the Company has taken no action
designed to, or reasonably likely to have the effect of, terminating the registration of the Stock under the Exchange Act or delisting
the Stock from the Nasdaq Market, nor has the Company received any notification that the Commission or the Nasdaq Market is contemplating
terminating such registration or listing. The Company is in compliance with the current listing standards of the Nasdaq Market. The Company
has caused a Notification of Listing of Additional Shares to be filed with the Nasdaq Market with respect to the Underwritten Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(eee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Form&nbsp;S-3
Eligibility; Shell Company</I>. The Company and the transactions contemplated by this Agreement meet the requirements for, and comply
with the conditions for the use of, Form&nbsp;S-3 under the Securities Act, including Instruction I.B.1 of Form&nbsp;S-3. The Company
is not a shell company (as defined in Rule&nbsp;405 under the Securities Act) and has not been a shell company for at least 12 calendar
months previously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(fff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Independent
Directors</I>. Each of the independent directors named in the Registration Statement, the Pricing Disclosure Package and Prospectus satisfies
the independence standards established by the Nasdaq Market and, with respect to members of the Company&rsquo;s audit committee, the enhanced
independence standards contained in Rule&nbsp;10A-3(b)(1)&nbsp;promulgated by the Commission under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ggg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Integration</I>. Neither the Company nor, to the Company&rsquo;s knowledge, any of its affiliates (within the meaning of Rule&nbsp;144
under the Securities Act) has, prior to the date hereof, made any offer or sale of any securities which could be &ldquo;integrated&rdquo;
(within the meaning of the Securities Act) with the offer and sale of the Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Further
Agreements of the Company</U>. The Company covenants and agrees with each Underwriter that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Required
Filings.</I> The Company will file the final Prospectus with the Commission within the time periods specified by Rule&nbsp;424(b)&nbsp;and
Rule&nbsp;430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule&nbsp;433
under the Securities Act; and the Company will file promptly all reports and any definitive proxy or information statements required to
be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act subsequent to
the date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the
Securities; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously
delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date
of this Agreement in such quantities as the Representatives may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Delivery
of Copies.</I> The Company will deliver, without charge, (i)&nbsp;to the Representatives upon request two signed copies of the Registration
Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents
incorporated by reference therein; and (ii)&nbsp;to each Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally
filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies
of the Prospectus (including all amendments and supplements thereto and each Issuer Free Writing Prospectus) as the Representatives may
reasonably request. As used herein, the term &ldquo;Prospectus Delivery Period&rdquo; means such period of time after the first date of
the offering of the Securities as in the opinion of counsel for the Underwriters a prospectus relating to the Securities is required by
law to be delivered (or required to be delivered but for Rule&nbsp;172 under the Securities Act) in connection with sales of the Securities
by any Underwriter or any dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Amendments
or Supplements,&nbsp;Issuer Free Writing Prospectuses.</I> Before making, preparing, using, authorizing, approving, referring to or filing
any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure
Package or the Prospectus, whether before or after the time that the Registration Statement becomes effective, the Company will furnish
to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement
for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such
proposed amendment or supplement to which the Representatives reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Notice
to the Representatives.</I> The Company will advise the Representatives promptly, and confirm such advice in writing (which confirmations
may be delivered by e-mail), (i)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (ii)&nbsp;when
any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any amendment to the Prospectus
has been filed or distributed; (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment
or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other
request by the Commission for any additional information; (iv)&nbsp;of the issuance by the Commission or any other applicable governmental
or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of
the Pricing Disclosure Package, the Prospectus or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A
of the Securities Act; (v)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which
the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus as then amended or supplemented would include
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances existing when the Prospectus, the Pricing Disclosure Package or any such Issuer Free Writing Prospectus is delivered
to a purchaser, not misleading; (vi)&nbsp;of the receipt by the Company of any notice of objection of the Commission to the use of the
Registration Statement or any post-effective amendment thereto pursuant to Rule&nbsp;401(g)(2)&nbsp;under the Securities Act; and (vii)&nbsp;of
the receipt by the Company of any notice with respect to any suspension of the qualification of the Securities for offer and sale in any
jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its commercially reasonable
best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending
the use of any of the Pricing Disclosure Package or the Prospectus or suspending any such qualification of the Securities and, if any
such order is issued, will obtain as soon as possible the withdrawal thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Ongoing
Compliance.</I> (1)&nbsp;If during the Prospectus Delivery Period (i)&nbsp;any event or development shall occur or condition shall exist
as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is
delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with applicable
law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with
the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements
to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that
the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and incorporated by reference
therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that
the Prospectus will comply with applicable law and (2)&nbsp;if at any time prior to the Closing Date (i)&nbsp;any event or development
shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include
any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light
of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary
to amend or supplement the Pricing Disclosure Package to comply with applicable law, the Company will promptly notify the Underwriters
thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish
to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure
Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements
in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing
Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Blue
Sky Compliance.</I> The Company will qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions
as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of
the Securities; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or
as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general
consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not
otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Earning
Statement. </I>The Company will make generally available to its security holders and the Representatives as soon as practicable an earning
statement that satisfies the provisions of Section&nbsp;11(a)&nbsp;of the Securities Act and Rule&nbsp;158 of the Commission promulgated
thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the &ldquo;effective
date&rdquo; (as defined in Rule&nbsp;158) of the Registration Statement; provided that the Company will be deemed to have furnished such
statements to its security holders and the Representatives to the extent they are filed on the Commission&rsquo;s Electronic Data Gathering,
Analysis, and Retrieval system (&ldquo;EDGAR&rdquo;) or any successor system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Clear
Market.</I> For a period of 45 days after the date of the final prospectus supplement relating to the offering of the Securities, the
Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or file with, or
submit to, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible
into or exercisable or exchangeable for Stock, or publicly disclose the intention to make any offer, sale, pledge, disposition, submission
or filing (other than filings on Form&nbsp;S-8 relating to the Company Stock Plans or in respect of the issuance of equity incentive awards
in reliance on the employment inducement exception under Nasdaq Listing Rule&nbsp;5635(c)(4)), or (ii)&nbsp;enter into any swap or other
agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities,
whether any such transaction described in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of Stock or such other securities,
in cash or otherwise, without the prior written consent of Leerink Partners LLC and J.P. Morgan Securities LLC (the &ldquo;Lock-Up Representatives&rdquo;)
other than (A)&nbsp;the Securities to be sold hereunder and the delivery of Warrant Shares upon exercise of the Warrants, (B)&nbsp;any
shares of Stock of the Company issued upon the exercise of options granted under Company Stock Plans, the exercise of any pre-funded warrants
or upon vesting of restricted stock units, issued or awarded by the Company prior to the date hereof and in each case, as described in
the Prospectus and (C)&nbsp;the filing by the Company of any registration statement on Form&nbsp;S-8 or a successor form thereto (x)&nbsp;relating
to a Company Stock Plan described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or (y)&nbsp;in respect
of the issuance of equity incentive awards in reliance on the employment inducement exception under Nasdaq Listing Rule&nbsp;5635(c)(4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Use
of Proceeds.</I> The Company will apply the net proceeds from the sale of the Securities as described in each of the Registration Statement,
the Pricing Disclosure Package and the Prospectus under the heading &ldquo;Use of Proceeds&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Stabilization.</I> Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, any action designed to or
that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Exchange
Listing.</I> The Company will use its reasonable best efforts to list, subject to notice of issuance, the Underwritten Shares on the Nasdaq
Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Reports.</I>
For a period of three years from the date of this Agreement, the Company will furnish to the Representatives, as soon as they are available,
copies of all reports or other communications (financial or other) furnished to holders of the Underwritten Shares or the Warrants and
copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic
quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements to the Representatives
to the extent they are filed on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Record
Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing
Prospectus that is not filed with the Commission in accordance with Rule&nbsp;433 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Agreements of the Underwriters</U>. Each Underwriter hereby represents and agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>It
has not used, authorized use of, referred to or participated in the planning for use of, and will not use, authorize use of, refer to
or participate in the planning for use of, any &ldquo;free writing prospectus&rdquo;, as defined in Rule&nbsp;405 under the Securities
Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into
the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no
&ldquo;issuer information&rdquo; (as defined in Rule&nbsp;433(h)(2)&nbsp;under the Securities Act) that was not included in a previously
filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c)&nbsp;or
Section&nbsp;4(c)&nbsp;above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such Underwriter
and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an &ldquo;Underwriter
Free Writing Prospectus&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>It
has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final terms
of the Securities unless such terms have previously been included in a free writing prospectus filed with the Commission; <U>provided</U>
that the Underwriters may use a term sheet, if any, substantially in the form of Annex B hereto without the consent of the Company; <U>provided
further</U> that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company,
prior to, or substantially concurrently with, the first use of such term sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>It
is not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering (and will promptly notify
the Company if any such proceeding against it is initiated during the Prospectus Delivery Period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conditions
of Underwriters&rsquo; Obligations</U>. The obligation of each Underwriter to purchase the Underwritten Securities on the Closing Date
as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following
additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Registration
Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding
for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the
Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case
of an Issuer Free Writing Prospectus, to the extent required by Rule&nbsp;433 under the Securities Act) and in accordance with Section&nbsp;4(a)&nbsp;hereof;
and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Representations
and Warranties.</I> The representations and warranties of the Company contained herein shall be true and correct on the date hereof and
on and as of the Closing Date; and the statements of the Company and its officers made in any certificates delivered pursuant to this
Agreement shall be true and correct on and as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(i)&nbsp;hereof shall have occurred or shall exist,
which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus
(excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable
or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date on the terms and in the manner contemplated
by this Agreement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Officer&rsquo;s
Certificate.</I> The Representatives shall have received on and as of the Closing Date, a certificate of the Chief Financial Officer of
the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives (i)&nbsp;confirming
that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge
of such officers, the representations set forth in Section&nbsp;3(b)&nbsp;hereof are true and correct, (ii)&nbsp;confirming that the other
representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements
and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date, and (iii)&nbsp;to the
effect set forth in paragraphs (a)&nbsp;and (c)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Comfort
Letters.</I> (i)&nbsp;On the date of this Agreement and on the Closing Date, PricewaterhouseCoopers LLP shall have furnished to the Representatives,
at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and
substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&rsquo;
&ldquo;comfort letters&rdquo; to underwriters with respect to the financial statements and certain financial information contained or
incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; <U>provided</U> that
the letter delivered on the Closing Date shall use a &ldquo;cut-off&rdquo; date no more than three business days prior to such Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)&nbsp;On the date of this Agreement
and on the Closing Date, the Company shall have furnished to the Representatives a certificate, dated the respective dates of delivery
thereof and addressed to the Underwriters, of its Chief Financial Officer with respect to certain financial data contained in the Pricing
Disclosure Package and the Prospectus, providing &ldquo;management comfort&rdquo; with respect to such information, in form and substance
reasonably satisfactory to the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Opinion
and 10b-5 Statement of Counsel for the Company.</I> Morgan, Lewis&nbsp;&amp; Bockius LLP, counsel for the Company, shall have furnished
to the Representatives, at the request of the Company, their written opinion and 10b-5 statement, dated the Closing Date and addressed
to the Underwriters, in form and substance reasonably satisfactory to the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Opinion
of Intellectual Property Counsel for the Company</I>. JA Kemp LLP, intellectual property counsel for the Company, shall have furnished
to the Representatives, at the request of the Company, their written opinion, dated the Closing Date and addressed to the Underwriters,
in form and substance reasonably satisfactory to the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Opinion
and 10b-5 Statement of Counsel for the Underwriters.</I> The Representatives shall have received on and as of the Closing Date, an opinion
and 10b-5 statement, addressed to the Underwriters, of Cravath, Swaine&nbsp;&amp; Moore LLP, counsel for the Underwriters, with respect
to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as
they may reasonably request to enable them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Legal Impediment to Issuance and Sale.</I> No action shall have been taken and no statute, rule, regulation or order shall have been enacted,
adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the
issuance or sale of the Securities; and no injunction or order of any federal, state or foreign court shall have been issued that would,
as of the Closing Date, prevent the issuance or sale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Good
Standing</I>. The Representatives shall have received on and as of the Closing Date, satisfactory evidence of the good standing of the
Company and its subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as
the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental
authorities of such jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Exchange
Listing.</I> The Underwritten Shares to be delivered on the Closing Date shall have been approved for listing on the Nasdaq Market, subject
to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Lock-up
Agreements</I>. The &ldquo;lock-up&rdquo; agreements, each substantially in the form of Exhibit&nbsp;A hereto, between the Representatives
and certain officers and directors of the Company relating to sales and certain other dispositions of shares of Stock or certain other
securities, delivered to the Representatives on or before the date hereof, shall be in full force and effect on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Warrants.</I>
The Representatives shall have received a form of Warrant in form and substance reasonably acceptable to the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Additional
Documents.</I> On or prior to the Closing Date, the Company shall have furnished to the Representatives such further certificates and
documents as the Representatives may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All opinions, letters, certificates and evidence
mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification
and Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Indemnification
of the Underwriters.</I> The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and
each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, reasonable legal fees
and other reasonable expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses
are incurred), joint or several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a
material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required
to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged
untrue statement of a material fact contained in the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus,
any &ldquo;issuer information&rdquo; filed or required to be filed pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act, any road
show as defined in Rule&nbsp;433(h)&nbsp;under the Securities Act (a &ldquo;road show&rdquo;) or any Pricing Disclosure Package (including
any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material
fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each
case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or
alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished
to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that
the only such information furnished by any Underwriter consists of the information described as such in paragraph (b)&nbsp;below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Indemnification
of the Company.</I> Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its
officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15
of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above,
but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission
or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished
to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus
(or any amendment or supplement thereto), any Issuer Free Writing Prospectus, any road show or any Pricing Disclosure Package (including
any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information
furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession
figure appearing in the fifth paragraph under the caption &ldquo;Underwriting.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Notice
and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be
brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this
Section&nbsp;7, such person (the &ldquo;Indemnified Person&rdquo;) shall promptly notify the person against whom such indemnification
may be sought (the &ldquo;Indemnifying Person&rdquo;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall
not relieve it from any liability that it may have under the preceding paragraphs of this Section&nbsp;7 except to the extent that it
has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>,
that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise
than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an Indemnified
Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory
to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent
the Indemnified Person and any others entitled to indemnification pursuant to this Section&nbsp;that the Indemnifying Person may designate
in such proceeding and shall pay the reasonable documented fees and expenses in such proceeding and shall pay the reasonable documented
fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the
right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the
Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed
within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall
have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to
the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying
Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential
differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding
or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any
local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any
such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated
in writing by the Representatives and any such separate firm for the Company, its directors, its officers who signed the Registration
Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable
for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees
to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing
sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees
and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding
effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person
of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request
prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any
settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification
could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such
Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the
subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure
to act by or on behalf of any Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Contribution.</I>
If the indemnification provided for in paragraphs (a)&nbsp;or (b)&nbsp;above is unavailable to an Indemnified Person or insufficient in
respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu
of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result
of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received
by the Company, on the one hand, and the Underwriters on the other, from the offering of the Securities or (ii)&nbsp;if the allocation
provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative
benefits referred to in clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriters on the other,
in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant
equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be
deemed to be in the same respective proportions as the net proceeds (after deducting underwriting discounts but before deducting expenses)
received by the Company from the sale of the Securities and the total underwriting discounts and commissions received by the Underwriters
in connection therewith, in each case as set forth in the table on the cover of the Prospectus, compared to the aggregate offering price
of the Securities. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company or by the Underwriters and the parties&rsquo; relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Limitation
on Liability.</I> The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to paragraph
(d)&nbsp;above were determined by <U>pro rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or
by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (d)&nbsp;above.
The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph
(d)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any reasonable documented legal or other reasonable
documented expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of
paragraphs (d)&nbsp;and (e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the
total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Securities exceeds the amount
of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities
Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&rsquo;
obligations to contribute pursuant to paragraphs (d)&nbsp;and (e)&nbsp;are several in proportion to their respective purchase obligations
hereunder and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Non-Exclusive
Remedies.</I> The remedies provided for in paragraphs (a)&nbsp;through (e)&nbsp;are not exclusive and shall not limit any rights or remedies
which may otherwise be available to any Indemnified Person at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Effectiveness
of Agreement</U>. This Agreement shall become effective as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.
This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after the execution and
delivery of this Agreement and on or prior to the Closing Date, (i)&nbsp;trading generally shall have been suspended or materially limited
on or by either of the New York Stock Exchange or The Nasdaq Stock Market; (ii)&nbsp;trading of any securities issued or guaranteed by
the Company shall have been suspended on any exchange or in any over-the-counter market; (iii)&nbsp;a general moratorium on commercial
banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak
or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States,
that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering,
sale or delivery of the Securities on the Closing Date on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure
Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Defaulting
Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If,
on the Closing Date, any Underwriter defaults on its obligation to purchase the Securities that it has agreed to purchase hereunder on
such date, the non-defaulting Underwriters may in their discretion arrange for the purchase of such Securities by other persons satisfactory
to the Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the non-defaulting
Underwriters do not arrange for the purchase of such Securities, then the Company shall be entitled to a further period of 36 hours within
which to procure other persons satisfactory to the non-defaulting Underwriters to purchase such Securities on such terms. If other persons
become obligated or agree to purchase the Securities of a defaulting Underwriter, either the non-defaulting Underwriters or the Company
may postpone the Closing Date for up to five full business days in order to effect any changes that in the opinion of counsel for the
Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or
arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that
effects any such changes. As used in this Agreement, the term &ldquo;Underwriter&rdquo; includes, for all purposes of this Agreement unless
the context otherwise requires, any person not listed in Schedule I hereto that, pursuant to this Section&nbsp;10, purchases Securities
that a defaulting Underwriter agreed but failed to purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If,
after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the non-defaulting
Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Securities that remain unpurchased on the
Closing Date does not exceed one-eleventh of the aggregate number of Securities to be purchased on such date, then the Company shall have
the right to require each non-defaulting Underwriter to purchase the number of Securities that such Underwriter agreed to purchase hereunder
on such date plus such Underwriter&rsquo;s pro rata share (based on the number of Securities that such Underwriter agreed to purchase
on such date) of the Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If,
after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the non-defaulting
Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Securities that remain unpurchased on the
Closing Date exceeds one-eleventh of the aggregate amount of Securities to be purchased on such date, or if the Company shall not exercise
the right described in paragraph (b)&nbsp;above, then this Agreement shall terminate without liability on the part of the non-defaulting
Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company,
except that the Company will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that
the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Nothing
contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any non-defaulting Underwriter
for damages caused by its default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payment
of Expenses</U><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Whether
or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or cause
to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the
costs incident to the authorization, issuance, sale, preparation and delivery of the Securities and any taxes payable in that connection;
(ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, any Issuer
Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto)
and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&rsquo;s counsel and independent accountants; (iv)&nbsp;the
fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the
Securities under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of
a Blue Sky Memorandum (including the related reasonable fees and expenses of counsel for the Underwriters), provided that the amount payable
by the Company pursuant to clause (iv)&nbsp;shall not exceed $10,000;&nbsp;(v)&nbsp;the cost of preparing stock certificates; (vi)&nbsp;the
costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and application fees incurred in connection with any
filing with, and clearance of the offering by, FINRA, <U>provided</U> that the amount payable by the Company pursuant to clause (vii)&nbsp;shall
not exceed $45,000; (viii)&nbsp;all expenses incurred by the Company in connection with any &ldquo;road show&rdquo; presentation to potential
investors; <U>provided</U>, <U>however</U>, that the Underwriters will pay all of the travel, lodging and other expenses of the Underwriters
or any of their employees incurred by them in connection with the &ldquo;road show&rdquo;, and <U>provided</U>, <U>further</U>, that the
Company will pay all of the cost of any aircraft chartered in connection with such road show with the prior approval of the Company; and
(ix)&nbsp;all expenses and application fees related to the listing of the Underwritten Shares on the Nasdaq Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
(i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii)&nbsp;the Company for any reason fails to tender the Securities
for delivery to the Underwriters (other than by reason of a default by any Underwriter) or, in the case of the Warrants, to the purchaser
thereof or (iii)&nbsp;the Underwriters decline to purchase the Securities for any reason permitted under this Agreement, the Company agrees
to reimburse the Underwriters for all out-of-pocket costs and expenses (including the fees and expenses of their counsel) reasonably incurred
by the Underwriters in connection with this Agreement and the offering contemplated hereby. For the avoidance of doubt, it is understood
that the Company shall not pay or reimburse any costs, fees or expenses incurred by an Underwriter that defaults on its obligations to
purchase the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Persons
Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred
to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable
right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any Underwriter
shall be deemed to be a successor merely by reason of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Survival</U>.
The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Underwriters contained
in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant
hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination
of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers, controlling
persons or affiliates referred to in Section&nbsp;7 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term &ldquo;affiliate&rdquo;
has the meaning set forth in Rule&nbsp;405 under the Securities Act; (b)&nbsp;the term &ldquo;business day&rdquo; means any day other
than a day on which banks are permitted or required to be closed in New York City; and (c)&nbsp;the term &ldquo;subsidiary&rdquo; has
the meaning set forth in Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October&nbsp;26,
2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the
Company, which information may include the name and address of their respective clients, as well as other information that will allow
the Underwriters to properly identify their respective clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Notices.</I>
All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted
and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives at (i)&nbsp;Leerink
Partners LLC, 1301 Avenue of the Americas, 5th Floor, New York, NY 10019; Attention: Stuart Nayman; (ii)&nbsp;J.P. Morgan Securities LLC,
270 Park Avenue, New York, NY 10017, (fax (212) 622-8358); Attention: Equity Syndicate Desk and (iii)&nbsp;Cantor Fitzgerald&nbsp;&amp;
Co., 110 East 59th Street, 6th Floor, New York, New York 10022; Attention: Equity Capital Markets or by email at prospectus@cantor.com.
Notices to the Company shall be given to it at 500 Unicorn Park, Suite&nbsp;303, Woburn, Massachusetts 01801, (fax: (781) 926-0870); Attention:
Shawn Glidden, with a copy to Morgan, Lewis&nbsp;&amp; Bockius LLP, One Federal Street, Boston, MA 02110; Attention: Timothy J. Corbett.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Governing
Law.</I> This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed
in accordance with the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Waiver
of Jury Trial.</I> Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating
to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Recognition
of the U.S. Special Resolution Regimes</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;In the event that any Underwriter
that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of
this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would
be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws
of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)&nbsp;In the event that any Underwriter
that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime,
Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent
than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the
United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">As used in this Section&nbsp;16(d):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;BHC Act Affiliate&rdquo; has the meaning assigned to
the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;Covered Entity&rdquo; means any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">(i)&nbsp;a &ldquo;covered entity&rdquo; as that term is
defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">(ii)&nbsp;a &ldquo;covered bank&rdquo; as that term is defined
in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">(iii)&nbsp;a &ldquo;covered FSI&rdquo; as that term is defined
in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;Default Right&rdquo; has the meaning assigned to that
term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;U.S. Special Resolution Regime&rdquo; means each of
(i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street
Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Counterparts.</I>
This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each
of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts may be delivered via
facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions
Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Amendments
or Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall
in any event be effective unless the same shall be in writing and signed by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Headings.</I>
The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation
of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with your understanding,
please indicate your acceptance of this Agreement by signing in the space provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPLIMUNE GROUP,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:<U></U></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%">/s/ Sushil Patel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;Name: Sushil Patel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title: Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;&ndash; Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted: As of the date first written above</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LEERINK PARTNERS LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sean Pitt</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Sean Pitt</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Senior Managing Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;&ndash; Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted: As of the date first written above</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Brandon
    Petillo</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Brandon Petillo</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: ECM Executive Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;&ndash; Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted: As of the date first written above</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CANTOR FITZGERALD&nbsp;&amp; CO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Asif Ahmed</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Asif Ahmed</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Co-Head of Equity Capital Markets, Managing Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;&ndash; Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Schedule
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">Number of</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">Number of Warrant</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Underwriters</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Underwritten Shares</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left">Leerink Partners LLC</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,880,596</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,094,536</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">J.P. Morgan Securities LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,880,596</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,094,536</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cantor Fitzgerald&nbsp;&amp; Co.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,940,298</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">547,268</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Annex
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>a.&#8239;</B></FONT></TD>
                                                                                                                         <TD STYLE="text-align: justify"><B>Pricing Information Provided Orally by the Underwriters</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 45%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Offering Price per Share:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;12.06</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif">Number of Underwritten Shares:</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font: 10pt Times New Roman, Times, Serif; text-align: right">9,701,490</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Offering Price per Warrant Share:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.0599</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Number of Warrant Shares:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,736,340</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Annex
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Exhibit&nbsp;A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM&nbsp;OF LOCK-UP AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[&#9679;], 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leerink Partners LLC<BR>
J.P. Morgan Securities LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cantor Fitzgerald&nbsp;&amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">As Representatives of the several <BR>
Underwriters
listed in Schedule I to the <BR>
Underwriting Agreement referred to <BR>
below,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Leerink Partners LLC<BR>
1301 Avenue of the Americas, 5th Floor<BR>
New York, New York 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o J.P. Morgan Securities LLC<BR>
270 Park Avenue<BR>
New York, New York 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Cantor Fitzgerald&nbsp;&amp; Co.<BR>
110 East 59th Street, 6th Floor<BR>
New York, New York 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Re:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Replimune
Group,&nbsp;Inc. &mdash;Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that you, as Representatives
(the &ldquo;Representatives&rdquo;) of the several Underwriters, propose to enter into an underwriting agreement (the &ldquo;Underwriting
Agreement&rdquo;) with Replimune Group,&nbsp;Inc., a Delaware corporation (the &ldquo;Company&rdquo;), providing for the offering (the
&ldquo;Offering&rdquo;) by the several Underwriters named in Schedule I to the Underwriting Agreement (the &ldquo;Underwriters&rdquo;),
of shares of Common Stock (as defined below) and pre-funded warrants to purchase shares of Common Stock (collectively, the &ldquo;Securities&rdquo;).
Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In consideration of the Underwriters&rsquo; agreement
to purchase and make the Offering of the Securities, and for other good and valuable consideration, receipt of which is hereby acknowledged,
the undersigned hereby agrees that, without the prior written consent of Lock-Up Representatives, the undersigned will not, during the
period beginning on the date of this letter agreement (this &ldquo;Letter Agreement&rdquo;) and ending 45 days after the date of the final
prospectus supplement relating to the Offering (the &ldquo;Prospectus&rdquo;) (such period, the &ldquo;Restricted Period&rdquo;), (1)&nbsp;offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock, $0.001 par value
per share, of the Company (the &ldquo;Common Stock&rdquo;) or any securities convertible into or exercisable or exchangeable for Common
Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned
in accordance with the rules&nbsp;and regulations of the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) and securities
which may be issued upon exercise of a stock option or warrant), (2)&nbsp;enter into any swap or other agreement that transfers, in whole
or in part, any of the economic consequences of ownership of the Common Stock or such other securities, whether any such transaction described
in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, (3)&nbsp;make
any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or
exercisable or exchangeable for Common Stock, or (4)&nbsp;publicly disclose the intention to do any of the foregoing. The undersigned
acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements
(including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof,
forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably
be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic
consequences of ownership, in whole or in part, directly or indirectly, of any such securities, whether any such transaction or arrangement
(or instrument provided for thereunder) would be settled by delivery of such securities, in cash or otherwise, in each case other than:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(A)&nbsp;transactions relating to shares of Common
Stock or other securities that the undersigned may purchase in the Offering (provided that the undersigned is not an officer or director
of the Company) or in open market transactions during the Restricted Period,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(B)&nbsp;the exercise, including by &ldquo;net&rdquo;
exercise, of any options or warrants to acquire shares of Common Stock, the conversion of any convertible security into Common Stock or
vesting of any restricted stock units, each as described in the registration statement related to the Offering, or issued pursuant to
an equity plan described in the registration statement related to the Offering, it being understood that any shares of Common Stock received
by the undersigned upon such exercise, conversion or vesting shall be subject to the restrictions on transfers set forth in this Letter
Agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(C)&nbsp;the sale or transfer to the Company of
such number of shares of Common Stock acquired by the undersigned in connection with the exercise of such options or warrants on a &ldquo;net&rdquo;
exercise basis or the vesting of restricted stock units described in the foregoing clause,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(D)&nbsp;the sale or transfer to the Company of
such number of shares of Common Stock necessary to generate only such amount of cash needed for the payment of taxes (including estimated
taxes) due as a result of the exercise of such options or warrants or the vesting of restricted stock units described in clause (C),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(E)&nbsp;transfers of shares of Common Stock or
such other securities as a bona fide gift or gifts (including without limitation to a charitable organization) or pursuant to a negotiated
divorce settlement, in each case in a transaction not involving a disposition for value,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(F)&nbsp;transfers by operation of law, including
pursuant to a qualified domestic relations order,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(G)&nbsp;distributions or transfers of shares of
Common Stock or other securities to subsidiaries, limited or general partners, members, managers, managing members, officers, directors,
employees, stockholders or affiliates (as such term is defined in Rule&nbsp;405 as promulgated by the Commission under the Securities
Act of 1933, as amended) of, or any investment fund or other entity that controls or manages, the undersigned or the undersigned&rsquo;s
affiliates (as defined above) or to any investment fund or other entity controlled or managed by the undersigned or under common control
of the undersigned, or if the undersigned is an investment company registered under the Investment Company Act of 1940, as amended (a
&ldquo;Mutual Fund&rdquo;), pursuant to a merger or reorganization with or into another Mutual Fund that shares the same investment adviser
registered pursuant to the requirements of the Investment Advisers Act of 1940, as amended, in each case in a transaction not involving
a disposition for value,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(H)&nbsp;transfers of shares of Common Stock or
other securities to any immediate family member, trusts for the direct or indirect benefit of the undersigned or one or more of the immediate
family members of the undersigned or any of their successors upon death, or any partnerships or limited liability company, the partners
or members of which consist of or are for the direct or indirect benefit of the undersigned and/or immediate family members or other dependent
of the undersigned (for purposes of this Letter Agreement, &ldquo;immediate family&rdquo; means any relationship by blood, marriage or
adoption, not more remote than first cousin), in each case in a transaction not involving a disposition for value,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(I)&nbsp;if the undersigned is a trust, transfers
to a trustor or beneficiary of the trust, in each case in a transaction not involving a disposition for value,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(J)&nbsp;transfers or dispositions of shares of
Common Stock or such other securities by will, other testamentary document or intestate succession to the legal representative, heir,
beneficiary or a member of the immediate family of the undersigned in a transaction not involving a disposition for value,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(K)&nbsp;conversion of preferred stock into shares
of Common Stock in connection with the consummation of the Offering, it being understood that any such shares of Common Stock received
by the undersigned upon such conversion shall be subject to the restrictions on transfer set forth in this Letter Agreement, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(L)&nbsp;transfers of shares of Common Stock made
pursuant to a contract, instruction or plan adopted pursuant to Rule&nbsp;10b5-1 of the Exchange Act (a &ldquo;Plan&rdquo;) prior to the
date hereof; <U>provided</U> that (1)&nbsp;no amendment, waiver or other modification shall be made to any such Plan during the Restricted
Period and (2)&nbsp;any filing under Section&nbsp;16(a)&nbsp;of the Exchange Act that is made in connection with any such transfers during
the Restricted Period shall state (x)&nbsp;that such transfers have been executed under a trading plan adopted pursuant to Rule&nbsp;10b5-1
under the Exchange Act and (y)&nbsp;the date of adoption of such plan, <U>provided</U> that in the case of any transfer or distribution
pursuant to clause (E), (G), (H), (I)&nbsp;or (J), each donee or distributee shall execute and deliver to the Representatives a lock-up
letter in the form of this Letter Agreement&#894; and provided, further, that in the case of any transfer or distribution pursuant to
clauses (B), (C), (D), (E)&nbsp;and (G)&nbsp;through (I), no filing by any party (donor, donee, transferor or transferee) under the Exchange
Act or other public announcement reporting a reduction in the beneficial ownership shall be required or shall be made voluntarily in connection
with such transfer or distribution (other than a filing on a Form&nbsp;5, Schedule 13G (or 13G/A) or 13F made after the expiration of
the Restricted Period referred to above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the foregoing paragraph shall not
apply to the establishment of a Plan by the undersigned after the date hereof for the sale or transfer of shares of Common Stock; <U>provided</U>
that such Plan does not provide for the sale or transfer of Common Stock during the Restricted Period and, no public announcement or filing
under the Exchange Act, if any, is required of or is voluntarily made by or on behalf of the undersigned or the Company regarding such
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The restrictions contained herein shall not apply
to any transfers, sales, tenders or other dispositions of Common Stock or any security convertible into or exercisable or exchangeable
for Common Stock pursuant to a bona fide third-party tender offer, merger, amalgamation, consolidation or other similar transaction that
is approved by the Company&rsquo;s Board of Directors and made to or involving all holders of the Common Stock or such other securities
pursuant to a change of control of the ownership of the Company (including, without limitation, the entry into any lock-up, voting or
similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common Stock or other
such securities in connection with any such transaction, or vote any securities in favor of any such transaction)&#894; <U>provided</U>
that if such bona fide third-party tender offer, merger, amalgamation, consolidation or other similar transaction is not completed, any
Common Stock or any security convertible into or exercisable or exchangeable for Common Stock subject to this Letter Agreement shall remain
subject to the restrictions contained in this Letter Agreement. For purposes of this Letter Agreement, &ldquo;change of control&rdquo;
shall mean the consummation of any bona fide third-party tender offer, merger, amalgamation, consolidation or other similar transaction
the result of which is that any &ldquo;person&rdquo; (as defined in Section&nbsp;13(d)(3)&nbsp;of the Exchange Act), or group of persons,
other than the Company, becomes the beneficial owner (as defined in Rules&nbsp;13d-3 and 13d-5 of the Exchange Act) of 50% of total voting
power of the voting stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any percentage of the Common Stock or any security
convertible into or exercisable or exchangeable for Common Stock held by any person or entity other than the undersigned that is subject
to a lock-up agreement related to the Offering similar in form to this Letter Agreement is released from any restrictions set forth in
such lock-up agreement, the same percentage (relative to the total holdings of the stockholder being released from such restrictions)
of the Common Stock or any security convertible into or exercisable or exchangeable for Common Stock held by the undersigned shall be
immediately and fully released from any remaining restrictions on transfer set forth in this Letter Agreement concurrently therewith&#894;
<U>provided</U>, <U>however</U>, that the Lock-Up Representatives will not be obligated to release the undersigned from the restrictions
on transfer set forth in this Letter Agreement unless the Lock-Up Representatives have first released more than 1%, in the aggregate,
of the Company&rsquo;s total outstanding shares of Common Stock (calculated on an as-converted basis pre- Offering) from such restrictions&#894;
<U>provided</U> that directors and officers may be released from such restrictions solely due to financial hardship as determined by the
Lock-Up Representatives in their sole judgment. In the event that, as a result of this paragraph, the undersigned is released from any
of its obligations under this Letter Agreement or, by virtue of this Letter Agreement, becomes entitled to offer, pledge, sell, contract
to sell, or otherwise transfer or dispose of any Common Stock or any security convertible into or exercisable or exchangeable for Common
Stock prior to the date that is 45 days after the date of the Prospectus, the Lock-Up Representatives shall notify the Company within
one (1)&nbsp;business day of the effective date of such release, and the Company, in turn, in consultation with the Lock-Up Representatives
shall notify the undersigned within two (2)&nbsp;business days thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In furtherance of the foregoing, the Company, and
any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline
to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned hereby represents and warrants
that the undersigned has full power and authority to enter into this Letter Agreement. All authority herein conferred or agreed to be
conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the
undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned acknowledges and agrees that the
Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned
with respect to the Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and
tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representatives may
be required or choose to provide certain Regulation Best Interest and Form&nbsp;CRS disclosures to you in connection with the Offering,
the Representatives and the other Underwriters are not making a recommendation to you to enter into this Letter Agreement and nothing
set forth in such disclosures is intended to suggest that the Representatives or any other Underwriter is making such a recommendation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding anything to the contrary contained
herein, if (1)&nbsp;the Company files an application with the Commission to withdraw the registration statement relating to the Offering
prior to the closing of the sale of the Securities in the Offering, (2)&nbsp;the Underwriting Agreement does not become effective by September&nbsp;30,
2026, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated
prior to payment for and delivery of the Common Stock to be sold thereunder, (3)&nbsp;the Representatives, on behalf of the Underwriters,
advise the Company, or the Company advises the Representatives, in writing, prior to the execution of the Underwriting Agreement, that
they have determined not to proceed with the Offering or (4)&nbsp;the closing of the Offering shall not have occurred on or before September&nbsp;30,
2026, then, in each case the undersigned shall be released from all obligations under this Letter Agreement. The undersigned understands
that the Underwriters are entering into the Underwriting Agreement and proceeding with the Offering in reliance upon this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Letter Agreement and any claim, controversy
or dispute arising under or related to this Letter Agreement shall be governed by and construed in accordance with the laws of the State
of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>NAME OF DIRECTOR / OFFICER</I>]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 49; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>tm2622673d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPLIMUNE GROUP,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF PRE-FUNDED WARRANT TO
PURCHASE COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Number of Shares: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">(subject to adjustment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant No.&nbsp;[&#9679;]</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Original Issue Date: [&#9679;], 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Replimune Group,&nbsp;Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;),
hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [&#9679;] or
its registered assigns (the &ldquo;<B>Holder</B>&rdquo;), is entitled, subject to the terms set forth below, to purchase from the Company
up to a total of [&#9679;] shares of common stock, $0.001 par value per share (the &ldquo;<B>Common Stock</B>&rdquo;), of the Company
(each such share, a &ldquo;<B>Warrant Share</B>&rdquo; and all such shares, the &ldquo;<B>Warrant Shares</B>&rdquo;) at an exercise price
per share equal to $0.0001 per share (as adjusted from time to time as provided in <U>Section&nbsp;9</U> herein, the &ldquo;<B>Exercise
Price</B>&rdquo;) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange,
transfer or replacement hereof, the &ldquo;<B>Warrant</B>&rdquo;) at any time and from time to time on or after the date hereof (the &ldquo;<B>Original
Issue Date</B>&rdquo;), subject to the following terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. <I>Definitions</I>. For purposes of this Warrant, the following
terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;&ldquo;<B>Affiliate</B>&rdquo; means
any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed
under Rule&nbsp;405 under the Securities Act, but only for so long as such control shall continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;&ldquo;<B>Commission</B>&rdquo; means
the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;&ldquo;<B>Closing Sale Price</B>&rdquo;
means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported
by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade
price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security
is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for
the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency
succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on
any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined
by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the
Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&rsquo;
determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for
any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;&ldquo;<B>Principal Trading Market</B>&rdquo;
means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading,
which, as of the Original Issue Date, shall be the Nasdaq Global Select Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e)&nbsp;&ldquo;<B>Registration Statement</B>&rdquo;
means the registration statement (File No. 333-287536), including a prospectus, filed with the Commission on May 23, 2025, as amended by Amendment No.1 to the registration
statement on Form S-3 filed on November 6, 2025, pursuant to  the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;&ldquo;<B>Securities Act</B>&rdquo; means
the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g)&nbsp;&ldquo;<B>Trading Day</B>&rdquo; means
any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, &ldquo;Trading
Day&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on
which banking institutions in New York City are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(h)&nbsp;&ldquo;<B>Transfer Agent</B>&rdquo; means Computershare Trust
Company, N.A., the Company&rsquo;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. <I>Issuance of Securities; Registration of Warrants</I>. The Warrant,
as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant
Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement
or an exchange meeting the requirements of Section&nbsp;3(a)(9)&nbsp;of the Securities Act as in effect on the Original Issue Date, the
Warrant Shares, are not &ldquo;restricted securities&rdquo; under Rule&nbsp;144 promulgated under the Securities Act as of the Original
Issue Date. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<B>Warrant
Register</B>&rdquo;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to
which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. <I>Registration of Transfers</I>. Subject to compliance with all
applicable securities laws and the rules&nbsp;of the Principal Trading Market, the Company shall, or will cause its Transfer Agent to,
register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all
applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the
form of this Warrant (any such new warrant, a &ldquo;<B>New Warrant</B>&rdquo;) evidencing the portion of this Warrant so transferred
shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall
be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such
transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company
shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&rsquo;s own expense any New Warrant under this <U>Section&nbsp;3</U>.
Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all
purposes, and the Company shall not be affected by any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. <I>Exercise and Duration of Warrants</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;All or any part of this Warrant shall
be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from time to time on or after the Original
Issue Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;The Holder may exercise this Warrant
by delivering to the Company (i)&nbsp;an exercise notice, in the form attached as <U>Schedule 1</U> hereto (the &ldquo;<B>Exercise Notice</B>&rdquo;),
completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being
exercised (which may take the form of a &ldquo;cashless exercise&rdquo; if so indicated in the Exercise Notice pursuant to <U>Section&nbsp;10</U>
below). The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof)
is an <B>&ldquo;Exercise Date</B>.&rdquo; The Holder shall not be required to deliver the original Warrant in order to effect an exercise
hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance
of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <B>The Holder and any assignee, by acceptance
of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the
Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount
stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. <I>Delivery of Warrant Shares</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;Upon exercise of this Warrant, the Company
shall promptly (but in no event later than one (1)&nbsp;Trading Day after the Exercise Date), upon the request of the Holder, cause the
Transfer Agent to credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to
the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;) through its Deposit
Withdrawal Agent Commission system or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program (the
&ldquo;<B>FAST Program</B>&rdquo;) or if the certificates are required to bear a legend regarding restriction on transferability, issue
and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&rsquo;s
share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant
to such exercise. The Holder, or any natural person or legal entity (each, a &ldquo;<B>Person</B>&rdquo;) so designated by the Holder
to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective
of the date such Warrant Shares are credited to the Holder&rsquo;s DTC account or the date of delivery of the certificates evidencing
such Warrant Shares, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;If by the close of the first (1st) Trading
Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares
in the manner required pursuant to <U>Section&nbsp;5(a)</U>&nbsp;or fails to cause the Transfer Agent to credit the Holder&rsquo;s DTC
account for such number of Warrant Shares to which the Holder is entitled, and if after such first (1st) Trading Day and prior to the
receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<B>Buy-In</B>&rdquo;),
then the Company shall, within three (3)&nbsp;Trading Days after the Holder&rsquo;s written request and in the Holder&rsquo;s sole discretion,
either (i)&nbsp;pay in cash to the Holder an amount equal to the Holder&rsquo;s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased, at which point the Company&rsquo;s obligation to deliver such certificate (and to
issue such Warrant Shares) or to cause the Holder&rsquo;s DTC account to be credited for such Warrant Shares shall terminate or (ii)&nbsp;promptly
deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to
the excess (if any) of Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so
purchased in the Buy-In over the product of (A)&nbsp;the number of shares of Common Stock purchased in the Buy-In, times (B)&nbsp;the
Closing Sale Price of a share of Common Stock on the Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;To the extent permitted by law and subject
to <U>Section&nbsp;5(b)</U>, the Company&rsquo;s obligations to cause the Transfer Agent to issue and deliver Warrant Shares in accordance
with and subject to the terms hereof (including the limitations set forth in <U>Section&nbsp;11</U> below) are absolute and unconditional,
irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof,
the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation
or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or
alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such
obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to <U>Section&nbsp;5(b)</U>, nothing
herein shall limit the Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver certificates
representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery of certificates
for shares of Common Stock, if any, upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer
tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such
certificates, all of which taxes and expenses shall be paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not
be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant
Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other
tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost,
stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in
lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by
the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures
and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation
of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&rsquo;s obligation
to issue the New Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. <I>Reservation of Warrant Shares</I>. The Company covenants that
it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued
and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as
herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free
from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and
restrictions of <U>Section&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance
and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully
paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock
may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange
or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior
written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant
Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this <U>Section&nbsp;9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;<U>Stock Dividends and Splits</U>. If
the Company, at any time while this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution
on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger
number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares of Common
Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in
each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock
outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately
after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution, <I>provided</I>, <I>however</I>, that if
such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed
accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph
as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii)&nbsp;of this paragraph shall
become effective immediately after the effective date of such subdivision or combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;<U>Pro Rata Distributions</U>. If the
Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i)&nbsp;evidences
of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii)&nbsp;rights
or warrants to subscribe for or purchase any security, or (iv)&nbsp;cash or any other asset (in each case, a &ldquo;<B>Distribution</B>&rdquo;),
other than a reclassification as to which <U>Section&nbsp;9(c)</U>&nbsp;applies, then in each such case, the Holder shall be entitled
to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the ownership limitation set forth in <U>Section&nbsp;11(a)</U>&nbsp;hereof) immediately before the date of which
a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to
be determined for the participation in such Distribution <I>provided</I>, <I>however</I>, to the extent that the Holder&rsquo;s right
to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in <U>Section&nbsp;11(a)</U>&nbsp;hereof,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common
Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit
of the Holder until the earlier of (i)&nbsp;such time, if ever, as the delivery to such Holder of such portion would not result in the
Holder exceeding the ownership limitation set forth in <U>Section&nbsp;11(a)</U>&nbsp;hereof and (ii)&nbsp;such time as the Holder has
exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;<U>Fundamental Transactions</U>. If,
at any time while this Warrant is outstanding, (i)&nbsp;the Company effects any merger or consolidation of the Company with or into another
Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately prior to such merger
or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger
or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one transaction
or a series of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person),
holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company
or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or
other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with
another Person whereby such other Person acquires more than  50% of the voting power of the capital stock of the Company (except for
any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same
proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any reclassification of
the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by <U>Section&nbsp;9(a)</U>&nbsp;above)
(in any such case, a &ldquo;<B>Fundamental Transaction</B>&rdquo;), then following such Fundamental Transaction the Holder shall have
the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled
to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the
holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise
contained herein (the &ldquo;<B>Alternate Consideration</B>&rdquo;). The Company shall not effect any Fundamental Transaction in which
the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate
Consideration is solely cash and the Company provides for the simultaneous &ldquo;cashless exercise&rdquo; of this Warrant pursuant to
<U>Section&nbsp;10</U> below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving
entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate
Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under
this Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous to a Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;<U>Number of Warrant Shares</U>. Simultaneously
with any adjustment to the Exercise Price pursuant to <U>Section&nbsp;9</U> (including any adjustment to the Exercise Price that would
have been effected but for the final sentence in this paragraph (d)), the number of Warrant Shares that may be purchased upon exercise
of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder
for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior
to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock
then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e)&nbsp;<U>Calculations</U>. All calculations
under this <U>Section&nbsp;9</U> shall be made to the nearest one-hundredth of one cent or the nearest share, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;<U>Notice of Adjustments</U>. Upon the
occurrence of each adjustment pursuant to this <U>Section&nbsp;9</U>, the Company at its expense will, at the written request of the Holder,
promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth
such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities
issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail
the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate
to the Holder and to the Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g)&nbsp;<U>Notice of Corporate Events</U>. If,
while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other distribution of cash, securities or other property
in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital
stock of the Company or any subsidiary, (ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder
approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs
of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the
Company shall deliver to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the applicable record or effective
date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; <I>provided</I>,
<I>however</I>, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required
to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any
agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section&nbsp;9(c)</U>, other
than a Fundamental Transaction under clause (iii)&nbsp;of <U>Section&nbsp;9(c)</U>, then, except if such notice and the contents thereof
shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction
at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10. <I>Payment of Cashless Exercise Price</I>. Notwithstanding anything
contained herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a &ldquo;cashless
exercise,&rdquo; in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected
pursuant to Section&nbsp;3(a)(9)&nbsp;of the Securities Act as determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">X = Y [(A-B)/A]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;X&rdquo; equals the number of Warrant Shares
to be issued to the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;Y&rdquo; equals the total number of Warrant
Shares with respect to which this Warrant is then being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;A&rdquo; equals the Closing Sale Price
per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;B&rdquo; equals the Exercise Price per
Warrant Share then in effect on the Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of Rule&nbsp;144 promulgated under the Securities Act,
it is intended, understood and acknowledged that the Warrant Shares issued in such a &ldquo;cashless exercise&rdquo; transaction shall
be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the
Original Issue Date (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise).
In the event that the Registration Statement or another registration statement registering the issuance of Warrant Shares is, for any
reason, not effective at the time of exercise of this Warrant, then this Warrant may only be exercised through a cashless exercise, as
set forth in this <U>Section&nbsp;10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In no event will the exercise of this Warrant be settled in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. <I>Limitations on Exercise</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;Notwithstanding anything to the contrary
contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant
for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise,
would cause (i)&nbsp;the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates and any other Persons
whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section&nbsp;13(d)&nbsp;of the
Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), to exceed 9.99% (the &ldquo;<B>Maximum Percentage</B>&rdquo;)
of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii)&nbsp;the combined
voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial
ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section&nbsp;13(d)&nbsp;of the Exchange Act to exceed
9.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes
of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares
of Common Stock as reflected in (x)&nbsp;the Company&rsquo;s most recent Form&nbsp;10-Q or Form&nbsp;10-K, as the case may be, filed with
the Commission prior to the Exercise Date, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other notice by the
Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder,
the Company shall within three (3)&nbsp;Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common
Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding
shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum
Percentage to any other percentage not in excess of 9.99% specified in such notice; provided that any such increase or decrease will
not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this <U>Section&nbsp;11(a)</U>,
the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other
Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section&nbsp;13(d)&nbsp;of
the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining
unexercised and non-cancelled portion of this Warrant by the Holder and (y)&nbsp;exercise or conversion of the unexercised, non-converted
or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities
of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred
stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation
contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common
Stock would be aggregated with the Holder&rsquo;s for purposes of Section&nbsp;13(d)&nbsp;of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;This <U>Section&nbsp;11</U> shall not
restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities
or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in <U>Section&nbsp;9(c)</U>&nbsp;of
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will
be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number
of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market
value (based on the Closing Sale Price) for any such fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13. <I>Notices</I>. Any and all notices or other communications or
deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective
on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile or confirmed e-mail prior
to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile or confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any
Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying
next business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery.
The addresses, facsimile numbers and e-mail addresses for such communications shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Replimune Group,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Shawn Glidden</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">500 Unicorn Park Drive, Suite&nbsp;103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Woburn, MA 01801</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Telephone: (781) 222-9600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Fax: (781) 926-0870</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: shawn.glidden@replimune.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">If to the Holder, to its address, facsimile number or e-mail
address set forth herein or on the books and records of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Or, in each of the above instances, to such other address, facsimile
number or e-mail address as the recipient party has specified by written notice given to each other party at least five (5)&nbsp;days
prior to the effectiveness of such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant
agent under this Warrant. Upon ten (10)&nbsp;days&rsquo; notice to the Holder, the Company may appoint a new warrant agent. Any corporation
into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company
or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all
of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act.
Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage
prepaid) to the Holder at the Holder&rsquo;s last address as shown on the Warrant Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15. <I>Miscellaneous</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;<U>No Rights as a Stockholder</U>. The
Holder, solely in such Person&rsquo;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed
the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the
Holder, solely in such Person&rsquo;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any
right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock,
consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or
otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise
of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase
any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted
by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;<U>Authorized Shares</U>. Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its
certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may
be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such
exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (iii)&nbsp;use
commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof as may be necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;<U>Successors and Assigns</U>. Subject
to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company
without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding
on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence,
nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy
or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors
and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;<U>Amendment and Waiver</U>. Except as
otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action herein prohibited, or omit
to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e)&nbsp;<U>Acceptance</U>. Receipt of this Warrant
by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;<U>Governing Law; Jurisdiction</U>. ALL
QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND
ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE
COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF
NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF THE WARRANT OR ANY OF THE DOCUMENTS DELIVERED HEREUNDER), AND
HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO
THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS
TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT
DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE
GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE
PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g)&nbsp;<U>Headings</U>. The headings herein
are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(h)&nbsp;<U>Severability</U>. In case any one
or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining
terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt
in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so
agreeing, shall incorporate such substitute provision in this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">IN WITNESS WHEREOF, the Company has caused this
Warrant to be duly executed by its authorized officer as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">REPLIMUNE GROUP,&nbsp;INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; width: 47%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: [&#9679;]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: [&#9679;]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;to Warrant</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF EXERCISE NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[To be executed by the Holder to purchase Warrant
Shares under the Warrant]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;The undersigned is the Holder of Warrant No.&nbsp;__ (the
&ldquo;Warrant&rdquo;) issued by Replimune Group,&nbsp;Inc., a Delaware corporation (the &ldquo;Company&rdquo;). Capitalized terms used
herein and not otherwise defined herein have the respective meanings set forth in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2)&nbsp;The undersigned hereby exercises its right to purchase Warrant
Shares pursuant to the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3)&nbsp;The Holder intends that payment of the Exercise Price shall
be made as (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash Exercise </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Cashless Exercise&rdquo; under Section&nbsp;10
    of the Warrant </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4)&nbsp;If the Holder has elected a Cash Exercise, the Holder shall
pay the sum of $ __________ in immediately available funds to the Company in accordance with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5)&nbsp;Pursuant to this Exercise Notice, the Company shall deliver
to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(6)&nbsp;By its delivery of this Exercise Notice, the undersigned represents
and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder, its Affiliates and any other Person whose
beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section&nbsp;13(d)&nbsp;of the Exchange
Act will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d)&nbsp;of
the Securities Exchange Act of 1934, as amended) permitted to be owned under Section&nbsp;11(a)&nbsp;of the Warrant to which this notice
relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 39%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Holder: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Signature must conform in all respects to name
of Holder as specified on the face of the Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>tm2622673d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit&nbsp;5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2622673d1_ex5-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August&nbsp;10, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Replimune Group,&nbsp;Inc.<BR>
500 Unicorn Park, Suite&nbsp;303<BR>
Woburn, MA 01801</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to Replimune Group,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the offering and sale by the Company of up to 9,701,490
shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;<U>Common Stock</U>&rdquo;)
and pre-funded warrants (the &ldquo;<U>Pre-Funded Warrants</U>&rdquo;) to purchase up to 2,736,340 shares of Common Stock (the &ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo;), pursuant to the Underwriting Agreement, dated August&nbsp;9, 2026 (the &ldquo;<U>Underwriting Agreement</U>&rdquo;),
by and among the Company, Leerink Partners LLC, J.P. Morgan Securities LLC and Cantor Fitgerald&nbsp;&amp; Co. (together, the &ldquo;<U>Underwriters</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this opinion letter, we have
examined the Registration Statement on Form&nbsp;S-3 (Registration No.&nbsp;333-287536) filed with the Securities and Exchange Commission
(the &ldquo;<U>SEC</U>&rdquo;) on May&nbsp;23, 2025, as amended by Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-3
filed on November&nbsp;6, 2025 (as so amended, the &ldquo;<U>Shelf Registration Statement</U>&rdquo;), pursuant to the Securities Act
of 1933, as amended, the Underwriting Agreement, the Pre-Funded Warrants and originals, or copies certified or otherwise identified to
our satisfaction, of the Third Amended and Restated Certificate of Incorporation (the &ldquo;<U>Restated Certificate</U>&rdquo;) and the
Amended and Restated Bylaws of the Company and such other documents, records and other instruments as we have deemed appropriate for purposes
of the opinion set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have assumed the genuineness of all signatures,
the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals
of all documents submitted to us as certified, facsimile or photostatic copies and the authenticity of the originals of all documents
submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the Pre-Funded Warrants, we have
assumed that, as of each and every time any of the Pre-Funded Warrants are exercised, the Company will have a sufficient number of authorized
and unissued shares of the Common Stock available for issuance under its Restated Certificate to permit full exercise of each of the Pre-Funded
Warrants in accordance with their terms without the breach or violation of any other agreement, commitment or obligation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the foregoing, we are of the opinion
that (i)&nbsp;the Shares have been duly authorized by the Company and, when issued and sold by the Company and delivered by the Company
against receipt of the purchase price therefor, in the manner contemplated by the Underwriting Agreement, will be validly issued, fully
paid and non-assessable; (ii)&nbsp;when the Pre-Funded Warrants are issued, sold and delivered in the manner and for the consideration
stated in the Shelf Registration Statement, such Pre-Funded Warrants will be valid and binding obligations of the Company, enforceable
against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and other laws of general applicability relating to or affecting creditors&rsquo; rights and to general equity principles; and (iii)&nbsp;the
Pre-Funded Warrant Shares, when issued and delivered by the Company upon exercise of the Pre-Funded Warrants in accordance with the terms
thereof, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The opinions expressed herein are limited to Delaware
General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top"><TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 25%"><B>Morgan, Lewis &amp; Bockius <FONT STYLE="font-variant: small-caps">llp</FONT></B></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>101 Park Avenue</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>New York, NY 10178-0060</TD>
    <TD><IMG SRC="tm2622673d1_ex5-1img002.jpg" ALT="" STYLE="width: 14px; height: 15px">+1.212.309.6000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>United States</TD>
    <TD><IMG SRC="tm2622673d1_ex5-1img002.jpg" ALT="" STYLE="width: 14px; height: 15px">+1.212.309.6001</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August&nbsp;10, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the reference to us under
the heading &ldquo;Legal Matters&rdquo; in the prospectus included in the Shelf Registration Statement, and to the filing of this opinion
as an exhibit to the Company&rsquo;s Current Report on Form&nbsp;8-K to be filed on or about the date hereof, which will be incorporated
by reference in the Shelf Registration Statement. In giving the foregoing consents, we do not thereby admit that wea re within the category
of persons whose consent is required under Section&nbsp;7 of the Act or the rules&nbsp;and regulations of the SEC thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ MORGAN, LEWIS&nbsp;&amp; BOCKIUS LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>tm2622673d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Replimune Announces Pricing of $150.0 Million
Underwritten Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>August&nbsp;10, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BOSTON, August&nbsp;10, 2026 (GLOBE NEWSWIRE)
-- Replimune Group,&nbsp;Inc. (Nasdaq: REPL) (&ldquo;Replimune&rdquo;), a commercial-stage biotechnology company pioneering the development
of novel oncolytic immunotherapies, today announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at
an offering price of $12.06 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,736,340 shares
of its common stock at a purchase price of $12.0599 per pre-funded warrant, which equals the offering price per share of the common stock
less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be
approximately $150&nbsp;million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities
in the offering are to be sold by Replimune. The offering is expected to close on August&nbsp;11, 2026, subject to the satisfaction of
customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leerink Partners, J.P. Morgan, and Cantor are
acting as the bookrunning managers for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities are being offered by Replimune
pursuant to its shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Replimune with the
Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on May 23, 2025, as amended by Amendment No. 1 to the Registration Statement
on Form S-3 filed with the SEC on November 6, 2025. A prospectus supplement relating to the offering, and the accompanying prospectus,
will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be
obtained, when available, by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement and
the accompanying prospectus, when available, may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street,
40th&nbsp;Floor, Boston, Massachusetts 02109, by telephone at (800)&nbsp;808-7525, ext. 6105, or by email at syndicate@leerink.com; J.P.
Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email: prospectus-eq_fi@jpmchase.com
and postsalemanualrequests@broadridge.com; and Cantor Fitzgerald&nbsp;&amp; Co., Attention: Equity Capital Markets, 110 East 59th Street,
6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any sale of securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Replimune</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Replimune Group,&nbsp;Inc., headquartered in Woburn,
MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies,
including the Company&rsquo;s first commercially available product TUDRIQEVTM (vusolimogene oderparepvec-wtpg), approved under accelerated
approval by the U.S. Food and Drug Administration in combination with nivolumab for the treatment of adults with advanced melanoma who
experienced disease progression on a PD-1 antibody-based regimen. Replimune&rsquo;s proprietary RPx platform is based on a potent HSV-1
backbone intended to maximize immunogenic cell death and induce a systemic anti-tumor immune response. Upon intratumor injection, RPx
causes direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens, alteration of the tumor
microenvironment, and when dosed in combination with an immune checkpoint inhibitor immunotherapy, it may ignite a systemic anti-tumor
response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities,
leading to the versatility to be developed alone or combined with a variety of other treatment options. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward looking statements
within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act
of 1934, as amended, including statements regarding the timing of closing of our offering, the gross proceeds we expect to receive from
our offering and other statements identified by words such as &ldquo;could,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo;
&ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; or similar expressions and
the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those
contemplated in such forward-looking statements. These factors include risks related to our limited experience in commercializing products
for sale, our ability to successfully verify the clinical benefit of TUDRIQEV in our ongoing confirmatory Phase 3 trial,&nbsp;IGNYTE-3,
our ability to meet our product manufacturing goal, the timing and scope of future regulatory approvals, the availability of combination
therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability
to identify additional product candidates, the impact of political and global macro factors and military conflicts, and other risks as
may be detailed from time to time in our Annual Reports on Form&nbsp;10-K and Quarterly Reports on Form&nbsp;10-Q and other reports we
file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied
by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake
no obligation to update or revise these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Inquiries<BR>
</B>Chris Brinzey<BR>
ICR Westwicke<BR>
339.970.2843<BR>
<U>chris.brinzey@westwicke.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Inquiries<BR>
</B>Arleen Goldenberg<BR>
Replimune<BR>
917.548.1582<BR>
<U>media@replimune.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>repl-20260809.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaWM+bOdzZR+WYkxtmB+bTmqXygrOP03Di3FwaTGMaUE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:repl="http://replimune.com/20260809" elementFormDefault="qualified" targetNamespace="http://replimune.com/20260809">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://replimune.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="repl-20260809_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="repl-20260809_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>repl-20260809_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>repl-20260809_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="repl-20260809.xsd#Cover" roleURI="http://replimune.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://replimune.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2622673d1_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2622673d1_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D .<# 2(  A$! Q$!_\0
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MJ]FDLX)+![+8$@:,Q;$XPI&,#TXK#\*^"-'\&K<KI*S@7)4R>;)N^[G&/S-
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1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2622673d1_ex5-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2622673d1_ex5-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 !0# 2(  A$! Q$!_\0
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D[H/PI\*>'K\7L%G)<SK]PW;B0(?4#&,^_6BB@#MJ*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 09, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  09,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">REPLIMUNE GROUP, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2082553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500
Unicorn Park Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Woburn<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">REPL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tm2622673d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://replimune.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>repl-20260809.xsd</File>
    <File>repl-20260809_lab.xml</File>
    <File>repl-20260809_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2622673d1_8k.htm">tm2622673d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2622673d1_8k.htm": {
   "nsprefix": "repl",
   "nsuri": "http://replimune.com/20260809",
   "dts": {
    "schema": {
     "local": [
      "repl-20260809.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "repl-20260809_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "repl-20260809_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2622673d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://replimune.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-08-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2622673d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-08-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2622673d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://replimune.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-26-093042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-093042-xbrl.zip
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M)V9_HE'1!UL-H(5M%2RQZNWNT@V:=M]*8].8^9@KMSTI^L)E>- \MS&0ZI!
ML3]GI#4-6W/YW(XH,\1[Y_:#Q7.>H3'__,@:NI[J1)$P*6KB9$IY5O\/HSF2
MM&OH54%B8FHL[]2AXKA/^U&[5F$@542585W4151X$*O377.K:"^),A4UPP7C
MNS#/E(Q==+8DI*.C^Z!,$_70O#;M1[8/0T[FY3B/)$">70R@I6ZPB'Z@.E1L
M:;E4@#U0 OGV4/F6>*L9<W'L/-(YL_VU7;$G7&HW^L<%1Q$@^#/,D<+K%BD"
MUT*DA#_2I505X ^50-Y_8/(N\X:$^>^4J(0JOH&0/A$#89]CPG8X1.(]441H
M9OE @)^J@<3?H%YX.#PB(1\O*.<VAR,"M)>7Z8'8_\3$[O;Y"L#?/MOSNSFU
MP-GO%0'B?_M:\)^X18K  U5,1N:4K@#L3\1 ZA>8U!T.47G?B@A*>R<%YS_X
ML(_L(:$>,AT2GO=H:+9I/^X2.10Y2LY9:1,5^[^4*##T/3$4.4H:6F&Q9N"#
M5*F#SGA'%;<:BAPE :TR63/S6Y&P9&-O^G])X^G/&Z>'K$]54,8H2:?+% K;
MXDZ#2.S##!_?8R64,4JNZ3.'PGE@_"C"1R*BZT]TXP-](H621LDQO?904#\H
M%A.U&;.P>M XU4)AHV26?H,HM"=D/8J,*S9C^>/ :NC.(E#V*&DER"Y*"$8B
ME&HI]VX7#V1JCL?-0$;>(;VB(#0<*/GF"ZRC!.4ZB@PNO?USQP3M^D)1*@<_
M(\(+@,?F*\'>>QGV'AP[2AY::?.58#][&?8S.':47+32)B;V@?EXKR9RY7@"
M[11#D:/DHA46,8%G9YI[]:#D,\MG1551/RD!18^8HOK-HN[P^4D>LK<72BAO
MQ'2UW!PFYP>I$\+_8\NJ*\ER/90Y8N+J,UKW#<8\[O:FA6LJT9$$RA<E5RVU
M4S=2&V%%B7OW/51 @:(DH&5F:N9Y)^VSCX44WONQIRHH5Y1,TF6J[H'7SB36
MSD-_[VOP##:48?781LT8ORN6F!X,9!RG8GN/QO%4S"&%XD5)_[SV:D8]EIR%
M+&%B_ME<(2I&>#GG,AT4,DJRYS96,^$'16VDJ;GLSN9QV:4&ZGXV<XV\/CV4
M.$JN5VT4E_Q(ZY2JE_(O*06- DK:!S5=]SA#P]0,>YMN;SJQ*V8<H\R)"LH:
M)>5SF:J9[1<Y4<0NUAMOXJGD[N4AI4(H890$SV.M9L@'_2C'>R2!@D7)[$KM
M((T)M^MP0<2<NF<OE"NA@%$R/9\YM+%W#AI[YR\<>U$R/I<I)+;YW'!S1-U/
M.9L3]THR;P'P.AM,XAZK=:_?RY;\V'7<*L[Z,30?RK$[I%#@.$LD??;J1IU&
M+*%1WJ4A$T2$)J7:K6MS9.?5I: !P%E#"32-<GO_.^7\DY K,:9$2T&C_%+?
M=X??600:!<1GB!5V44+P3?+44%+91%#E. 8<4BARQ&>'#GLX<R_S2<V[<T_^
MP@X?<5<)*'C$AXA^LTCSTQ)J^\R>Z0>2D&T/??Q=):#\$1\H^LVBS9]7 W/B
MF4O_,_,C(90VXE384FLHD,<QX?PFU4Q0[1U;CH10R(AS7DNMH4"^C:F:FT'M
MHY*K9+%=V^F#[2@ A8XXL]5K%0?^^N<Z\GS]FY=\B1K\=@)$[$Z36*_="$,[
MD2(_DXN(* =UGQ[*'75AI=MHS>3ODP55^]=/66=&)F_S37JH+@6- DJZ"C6-
M<V[=6\GO/;4>Z*"\$1/3,F,X:Z;2*6?AD$OBO2X_D$'Y(F:A);90\-X0\:32
M91)N'I0,*;6/3_3N: ,D1, *H"%!S$]?A +G=H&,8[N82(9/XX4QK>_3)'M]
MJ>F?]Z:!MQPT-)B+. '&D:Z"],^%7C2ZV3S2&55VFL*$KI,;T]"3_Z((4!P:
M']0W"H$QE(3ILGWBZ\YLL&^HS;^QO^Q;6,V6_P%02P,$%     @ 05X*7<)T
M.9[U&   L8,  !(   !T;3(V,C(V-S-D,5\X:RYH=&WM/6M7VDK7W_D5\_*<
MBUV':[@H:GD6(O;05E'0:OO%-9 !4D-")XE ?_V[]\PD)! 0+;;ZK':=HY+,
M[+UGS[[/3CC\[W1DDGO&'<.VWOZ=S^3^)LSJV;IA#=[^7>O4F\V__UM-' Y=
M& 9#+>=M<NBZX_UL=C*99":%C,T'V7RE4LE.<4Q2#MJ?QH[3<KE\]N;T8Z<W
M9".:-BS'I5:/!9-,P[I;#1_O!D.[W#0B0_&*CZ2070(-=_7YA/#@<E;>C QU
M8X>6Y%#7'VHX=E'+[ZZC0XX()DQ7C<TCS;!"=G/4_C@?[L:/GP_-NIQ:3M_F
M(^K"%B*D4CJGI;5R"$C:8;T((/B<&=CW#\+92Q?R/IRES8FN%&]WJ1-P7&<+
M[/9QP@V8H97\@9Z3'E Z#@;WJ=,58-6-Q<'<-ID3.UK<B0SOV9[E\ED\(>IF
M9(+#W670<#$RB+.Q&8S"#\;(LUBF9X]P6#FWEZLD46<8U:L)@O\.7<,U6?4P
M*W\G#D?,I00AI-DWS[A_FZS;ELLL-WTY&P,+>_+3VZ3+IFY6*%869F4ER,/_
M2Z?)B<%,?9]TF'M SNB([9.I/CT@S6/QQVU.:]Q>=?[4CM_5:N?P"^DGZ?2&
MDPO:+:[K-K*X6W]QF\,I[@:3GC"[5+EE("U /?Q7&S%+A__=$Y,.;OO4=-@C
M(-5"D!H6[,*L#J X-9N6SJ8?V.PV![9IM[!;*14V!UL^ AX?W^9OE9I+^'#I
M$2"TV\Z0<N;<:K?"J$D8CKCV"##'2,FY E58(F@5[*ZMSXCCSDSV-MD'H=LG
M^=S8)9?&"$:<L0EIVR-JI>2%%.#G1A]E6S?N_6FZX8Q-.MLGEFTQO&=,]U%.
M&0?A%Q\,76<6:@)^@E%GW@C@]*243]TVZ[]-UIQ6'R4$;0ZH#S'TM\D3VG-S
M^*^0)!8L&G Q8S\B",FJD(3#; 3RC^ JAG'%BDJR.I>5.,39\)J1#,[ZC(-7
M98ZXCY9RWQ$N$,@APJ_M#SE2AOJ6]A4E,W7TI+KM@EEXFW2,T=AD: H4F@AD
MB<JQ/:XPP2"Q[?MJ\6*A"XM7!LH?R<2"_8O!94/'&WV#<2((9['>I-[\$.7-
MXN0 638.F\(U!D;:^A()X,^Y>TQ=5IU3[\.9WUN<!:*R8HY_9X&D,';_FF)?
MA*6>94A^@G(M,G'$J.-Q5E5*N ]#?%#^K0A\A!4/7.KS*OAJ\6+,$Q',C<8B
M$M!PV+@EAN),(>S4M?G\[J/7ODA>#,P0QF-FV2/#>@#G@_Q81!H#UK\=7OXB
M&Y7JS35-JKRR>8=9F%M-)!*'X\=:U@,RHGQ@6/L$A^8."(I=FIK& "[U0%L8
M3U;_^D^^G#LXS(ZKSX9" 0\YGK9GLO0Y'0B?&[;^$EK:M<?["$U][-JN:X_$
ME8FANT.D+/=G,C*S:W/@EYQY9-+>'=& (L<V#?V J)L^''D_/[^/RTT[QG=P
MA'!USA1DO?H9HCX;(?_7[,S>=G:F6[TZ:UXVCDGGLG;9Z!QFN]7G1MAIU*_:
MS<MFHT-J9\>D<5/_MW;VKD'JK=/39J?3;)VMH6)+ MFM7E-G"$FI:\/\XTP]
M0[1<J5C9(N8M:]83M AF$NJY=J T6NE!G7DY.A'EWS8Y^&R2?=)JGY)#9TPM
MX0PQDJ[D-)$JI-/'=L_#,!,SLMM>D,;,$YKO%^XW/CN]^/=380_ /3'>K(3C
MS3#.9'4O_6$QOCS,(K75WV+_0L7^^>P?V.!VX^R2M!OGK?;ES["XYQYW/&JY
MQ+5A8@_+0B1?(#8G^=*._N9GD&#WB3MDB-WCAFL P,:T-Z06[%ZMYQ*XG:\4
MBB]7&^(7AGD'TMYF8YN[9,?_S"A$F<QQ";N'D0DN;C/]S;ZDB0!#%HW5WH*Q
M.A?I2T/F-O%6J]6NS#[T<U:-5AYEM61M\&W2F+K[.D ?P=BA3F<S()M94:N6
MS\59M0AQR6K-&WBPV$J*()K?ENZ56[JM>>5%&2\H&9?%F#8;& X6JUVL@\6+
M>.[?Z]W^U6ZKLUMXLF/.YY<+05'<R2K8XH_-TZNS!GG7;EV=ITCSK)YY?D&.
MY]Q.8PJD"YK1F/" 5D(=XHQ9#TLP.C& M:Y#P(J";>%O?NO62]0MEW9-!CMK
MFB [/3R+2X)%Q<]CJNO^YT>C#.7B08K=LTV3CAU8M_^7J 0=NJHD<NCJ/J)[
MQEVC1TU?\H"3 <R"]N<*A1;:_.@2<XP=R$7L0-/JV1P<I#BNZKC@4>KR/*=N
MZRO,PL3)NX.3RO&E5WZJY\.3-"PWNFS,[7O4M277IRW;C;6T0CS 3#H!)[K6
M<J@_7?W!;9%%D[D>_#D7K@UF_^1-C1KW$\-DL/HNX_$[>&0U^$TAURQ_^ '#
M7EC>H#E>+&#GTX6]4F5]1/(_NAV[D>VXI-.F*M[WA.RNVYMKH_CUJWE]U#X?
M/'UO8DY?5A !Z;&6UG)[6FGY%&;%3L$/_BC;MD5>[PBUQ^3)AHR&DZ^0T#BZ
M(;*JPR[/5A/@LXVPG7CS>"%[O&1M<X5U>S0R'"=8$"H5D9OUZM;2;'=(8S0V
M[1GC<C51&8Q;5R!>6>&^JR\NJEK'HE46N:;KG#F.^O71L%@^7OT_S\Y&3>;=
M63?*LCS1 I26+4 ,#<EJ*9=+7%D&*(Q%SBF_(\?<N(]QH2$3\+RUBD4^YA_@
MHQ;/Q[+7>N]UKD_<W ^XN/(F3-22U8YG@%$JY-9;T"W5<S?F7#&.<W7XL\4O
M[8D5S[<3YU/C>]FX*!?HT_FVNY)O<_3)ZK7=];BU@F6II8)RK" (=]#BYQ!%
M@M5?$;#6+S]^* ^ZC0LG__0U[:U<TP(-R>II;<6BEM9T$K>F<QLB8_.+,5X=
M@I<:L^MWQ?<-]J7X]!555JXH0@&$<OF]7/Y9\O%E20[./N51Z-A=/@S%O')'
M48HI^I@#VXTQ-0F;LI[G@OV"R^!B$!'<,CU,]0@LA^!Z7FBN'J_6\U+)7__9
MT_*[!PX,,]EX:%N,6,)YAM:8@.R'@@#HD(:"0=A9%+>Z$C?4PAH,72U@0_=F
MD#MA=V[_[LD"ID6JEV&<R>KNWBJ!>K.D)#5%]4<;0I5S7/FZ^'FW=$6O.]UW
MM5WMZ91'BE:+>)-53=/2E7(N]^J*K5$A^^HY$(K-DM7ZD/7NQ!$!'4-"#@J%
M07;7GI(N,^T),>3YP0DD\&0O_8'T#1,URG 2!C98ZDS'PPW'&'FF2RUF>XXY
M(PY$>$Y_)F:J"787$,O 3QU)A,IK'L#AA%HS_U[?-@$YSL,B@8$1L;/_/'R=
M%XK"A:'%PM$346[<U>'RC0/S8.L60WH_QUU(C^-&1"&:K._&!/KI/AT9YFR?
M7 ,7D#/.<JCKFY5K;K@@#IC >):*\)UX+=5JG)_TM>][Y=TGGYYT;=MDU!*=
MBPOZ&RD>Q9(EV;-WL%*%0PG)G'>+# MVL%($ABM$L( P)C(.'0!BP9,4M9*2
M]H53.3R,V\GODOI).]2>]9/_:85<!BA\HP0'L[$@%?MQQ9,_,UK)L'[KX!9U
MT$\W.[9I]$":K,$IV' PY.:*I@M[='5>GGSI?#6>0P$CQ<%EFIY#^^988),E
MFF75RQ=I.J^%M"]R$/[K=:^8RT@2?ZO?JU(_/]<^YPS]#/:2BP8D#(YXJ]]?
M%:V>Y#N-]],VN[:>10TC=>#5M#V'.@*V="^$[D&OF"_J:6VG^^:%*Z<D\K=Z
MOBKU;,2K9]-Q/,8?5-)._^O]MUQ1RXT?5VW94$E+:Y1TB<*7H:H%EB[N]%ZX
MJBHBWVPF,>&3E9^GUMM-Z*6&A!(*F5XS#@GZ.*X-4=A;E6[#QCU[=OT+VS >
M.B9;-%,+CTYT%SM=GNDP^1*?;)5=C+TAZ9G4<=8=^@6GX>L?I8B9N?7U!5KU
MP+:%6X1$+?>24Q0">3[8F8VZMKGCK#WJ?$&KWFQ7SU0WF=A4YIM*T,#)T( K
M<S5=<<Z^QNLN2^XFIY-^=[ZR%;.\UA62%^\ [^VAVVV!^GY^7)0:<7.1P[1%
MO,DJ>CU@2,>U>W<I,J:<W%/38^2/7":7RY,Q/C,Y7-?=$[/;CQ2.;?:$K&BZ
M4K(NI3R>V8V33Y5F[F*FNT\_N=0B)W 1I++=<H/PX>4RL[X@O'[LL;J3]>RS
M=UWZ=G3?K#^Y65NTK*'JQG6K:7MQPAVF"\P<^-@SZNCTFQ1R<DKY'7/)QX_U
M5;LA+.*.FO3.M+O4!)Z8X+W5Y-?<.!$D"$_T),EJT](Q1F6)[HSTQ!'&"#L8
M)D,F>H,6SA<,AP :"'"1H@$9<'OB#C'4'>.9 W6(SOJ&)5M[99DV5R++3T[,
M'Y@H)':0/;L'HF+J#S9$4_ 8FX*Q34G&RUHWK<7 BGL*@_A ,82=SS.<A \V
M0QHK%O&DW*@2.8/V0;\3D.L2<+Q2?7_O?;\V&L5)ZW&M ANF13''T['$;9H1
M;;-[Y:4K1A]$/;%"U/&\6.H-B>J-L70D-P2M$.8&M,*R1>K@.4R, GK5P1^^
M\,80Z81\Z!_W-X&XS!DBGQB &H73 FI!(3B[-QR8![I&K1X6:6E/O$(&!^/;
MAG3*=4<>^>FK\I;"#GTC=T I55B3,IOI@2\U+U\\?MF3Y*' ./9)\M"3YB^K
M\?\Y.([4'L#H;Q[620"H(%U$/<M,7/G$?7A[\EI,>TL9N3=?0(BL\!K5VQ&6
ML'-&[])=!BH(%(X%Q6&,Y1B$2,4C,89W\D5O8K?:=-E(0MW+0!K1$I%! Q\,
M=#*OK$]#703KS1!H+B/*22V+R"< )0'J,< 4/A4IWSF5 &_IC5/R=M/J9<@.
M6DSL)])R!\J)BD_Y@S=$1.HB" )["T945/@F7)ZKT0%GLD(8!G$5'E+SAP00
MA0/XR&"5UEWBG'+78MS!J#=%WF?.,^34Y@- % J+Q#UP!*0.=A]<QHGA?A\P
M3DU=+N(O.AH?D+J=P5A)KD(,#%#N8)Z-()9(9/Z@!,!/B2(1^I1[9H)?C%L3
MT.J#38'O,JE8)? &!QL.NJ8>$\0Z5!9N "L= !<&ZG'42FHWET\5*SFBWABE
M7%:(\]C7A2X3$V!'Y 9A_LH7RP2+0UQCSM)]3_C?">7HJQVD"7PEN$'PT%IJ
MMU!.%8H/X"1+.!,*)Y:$3R2":X4@($ M/LRB"+VB3@U<\B=D"*8^<A4@#:9)
MN@S-H4ZH*R#9:@)V\O7P8^*/O);)E>=)OU@T#HVA:PDDM98A$@&Q5*D(F,M0
M4JH2 ]8=0E&!"@8F)/(%:&!<92 O5V1B&R)^%I4*L#%LRG@/8IS0<%'W<3SX
ML8Q:LB=>B40<30T+I ,T',P&GX$0PNX[<%-5YY$U2@@,M"<P13?D+=BIGFD[
M #(E0CS(-D6$!0L*]52!X#,NWM\C@KC@NH",UF9D!0W[B7D+5Z2Y$A=I&K1K
MF%*%5[:WJ-0IA0D7'8D04C)@85FIT)H$(3T;C+;8;\43IB<@4W-7\VX"A@R6
MK6.AS9P)$D%!QK8C]4%LQ]RB(0XJ;\B'/'L$'\]VI"42L$# F *$:+O,@HS1
M32C=&H-I0V(7U2-"5.;5^YO+%5H(NI!0DB_*_4(19\0%I(3V724-NC**ON7,
MD!H9@M[";;@:!W=$9R+W"+0*P2C9\%,6"0'DV!Z(U#\A? X^GTO[V'HH]W%B
M>V @Y*YAX@%;:4\L,H)8":" U:AD*I4_?5,IFVN%/&QN0FW/%0HFNB-'(Z8C
M:G.6D P8&/=X@X$YZ8E\1HB@O[#-6 $J!S&>(QZ!TIGZ6U0=P%YAG0W#,>07
MZ :;]E2+M%@9EDED6B5\N0N6BSHN*>=A5V:.6A :+0 -$-!V*5E6:_[?$%ZU
M&,)@'#8*.0G8?!?24Q>YTV,,LL\^MT=BY;XO"YR,:)"=BHD@/W_DBP"90&YI
M&OA&);G/L&E>3^A])'K2#4<DNKX]\Q_S$I\3/CGZ'">;CIF%UFI,9T*GNK/(
M=I!C9D+HPH..6>61UCE+$!0$*U)ZV-UN8"%!H!*T"P(<"2?S>3^>=+SN5R6V
M<U^DO$O(YTAC'BP!T'69;,D"+.%<'@GTN]N%9Q&/40A3#,1@J[&DH),ND)WP
M0')F9^2M0J&0UO9V2X7R&^PPQF (]7[!ZR W@O+ _.&Z2+@SOQQ$.3#BE,XD
M(JT@N% *>RW<C. =FG.:\G%K(ZO7EI"$BV7=,S0Y\E998B0[^-8!VT<:B5$[
M0V;V5^"9QZR+/(_ZXT2,/XX&GY'A04BWQ;=3_4I;$.^D$[X"8:4RWABCNU,R
M1[&..S2ZZ&[RF;R0MV)&R0'(?]WC''=>O:8F(@![Z0^856#$(9,0$D+-!C8^
MTZ$SI\>-<;AK'N.UP"&MB'[6&0$D'@/=X%46,-#@F/L9G+DS%.W@E:B^GP+G
M+A:);JIGCP.;8X\-2Y$F,[D4)'L3PPFG:D?@&PT/$[OSI1S*A$0)@L8 7FQ.
M-3=N8F]B#9L5-=C ^8A->'@G0CLIKY4R^=?O\A;J _F<;]#1_/F^$)F.HHR)
MI8-M(Z:(*ZAE@</JB=T:RGQ&/,;1C[ Z*A$8B42 X+F+ZT("%-$55:VH@*)
MP,9<^_5S^HP9P;D3^GKPC9X('*W$1N)GJ;R"^=9$,@;C3X@]P,4";M=S69#@
M"M5D<$]-=&0'=/" 37A<UYLEQ)BY/9>&I0O;@HA ?Y3)P+]3@AJ)65P2L8\U
M"S12A*XA8&(ZO@-;/9X??C ?;\KT6A@2GZS4 L%< O?#= B>3#KI>Z8*26$1
M/.SKX)*R8>I9\GG.&:(+0#B2%S-%LZ(P$:;PA0K?)F5H[7<9^E65H2M8ACX)
M#K^"B,T/5*7N/V-M^D5WX\4V-#TDS 'J/[?9E@:[%O%59W;FH7?6;/9NF@V7
ML[>W[>4<SR/)->]TV6AKJH>4R'?MNR.MK&GEW8*>OV73?#J?&;JC;1(.,75
M*8WR/8[+/Y&R%9&W+K+XF$.9Q65LB^G%[2^MN!VF/P-E\Y@I-C%[+AZ7MK^2
MTG9X_ R4M1Z7T[TBGFN%%\OT.@3XHD*T82*](T]?9 *_F+>^>:X]J52VOW+,
M K>Q*<]!V[G(9=LJEUTV[7X^O6&N_./;LCV_FBO&Q3+Q#-^BE,/Z1$H@\> +
M)#@5U2_D+A5%&[(C>P1=63)HBJ]7(_C]:J^KX56^'=_F$\KU]$?;OD.)F$?\
M_Q/])Y<;E#82_C$VEC61&<14S'#FZ0_6Z501;\2HI91'M?RI.OQN;7U';KB,
M+0]NH_/SC<3R_+@NW&5 XI#(L.YM$R25&\Z=3-A Y4%?86WR\'U^(AY:&?:"
M<-VW#/[Q2R)RXN27:_T3%?^@-%+3Q$'RO8<AZ,'W0HDCB8F-W9/R;-OQB_@]
M+*FD5/'>ORCI</S+_E&(?*.+LSAZ1&>+E\8FM9;&C6W\QCW(;!=O.,,X(O!8
M;>E:>& "RT(&V!K*D7-HC8/>!'%,BWTV8#Q4.=QV5'4\0WR]BQ$UK'_C&2EP
M?V2(=@!.!A[%^)%)2'W/];CH 1&6"#8Y)2K/.#-T$D;)/>4&D]7KE4(Q4B^U
MD34P*HII,QOWTN.BFX';IFHS$"/$=I$>Q5Y;,(T>-?&,P#-%DT]"-T1-SW_'
M 38DR--*7+OHNQ[!SK@R+A""T%_)B9# IDC7<P573&"W/!Z4QTUJ7?+\N0MF
MFL'23!!@B1</^+&6C[\!(ZZI9EE(M+0&3M0<Y'-8:8>U7GCBU=E _ZIQ%R&!
MYVK,1!Z[A$[Z&G6Y-<IV8%\QE@QM<:CBH2Z,QV;T3 0[CD7A6[U<R!\JSB;D
MP6BTP-V"12WLA-RDI<U(!$?'_L!YF=4014O\\CFEK _LSEH9!IKIG>QLH<%9
MD+ :6*ZU^RG9X88] &/Q[G*.7Y'))6*33E+(2E$R=>D=JD/X[4S8Z#W652E7
M=FPC?(>MH_9ENK)-:JB%WS74EUU#7?VE6LUW9[7+J_;:K_!Z4<2O#:;.%P[K
ME<X*_7I2Y!+S0(?N@<D0SD67QW72M*IN$ >(E/T(> +594-J]OV^$V$MY( $
M&AD/>X0%..J!^^$0YNO/9 5>3]$ZMO(+D#!M>9O4MES27?SJ#-7E+;X_X\<J
MO LU[5)N?5%[Q5L]XD<5=Z/#?F$6C-^ALQ^;T<<FQ]M#?#3;7W>4L-[Y;%.*
MLDZ6=#QG:)C@%UUF_M"Q0%SQX'D+"F'2R2NCO3XT6!^LN/_6VI9X:RU_;36.
M!^.KX@%IB6,G9Y]\Q)[3GQ%N+7#[!UXV_$MB)OEOHV\MWSNZ%8]CRLPX^+)S
M]GYZ\E7/?1C<U2Z&7[(U??I5:]W9-\-^W1O7.[-ZT[)UQYF:5OO?+YQEV__8
MKE9JV^^.C'>]W=+WX9'QWGI/RQ>?NU_OZ]/!5ZUP\Z&I7WRVM=.2_9W=T<+U
MA_ZP6[S[U)WN?2MF[[6C=S=W[\Z_M$['E].2W>TSMW?U;7A9_](^-1O3X?&'
ML_>[]6Z]5>>E<OO;S?7)=&1]&APW/^V^'Y3SWN#JOD@;]S??.G:_^^G35+O@
M'7IY\?6B=92].SNU)W?=ULC[UVG?U'/7;>/Z^.IR=C0;F_?6S6?/NLB>FI_U
MDT'YGWOGXGRO\$^M=M2^^Z:^13Z+W]&.OX?NR*S^/U!+ P04    " !!7@I=
MIDU<ND^K   ^W@, %0   '1M,C8R,C8W,V0Q7V5X,2TQ+FAT;>R]>W/;5I8O
M^C^K^!UP^\SMDJH@10\_XC@G58ILISWM)"[;F9ZY_X$D*"$F 08 ):L__5W/
MO=?&@Z1DT6$\.C6G8Y'@QGZLO=[KM[[_QX>?W_PP''S_CY=G+^"_$?Z_[S^\
M_O#FY0_??\/_A6^_D:^___'7%_\3O?_P/V]>_M^_38N\_BXZ/EK4T8=LGE;1
M+^EU]*Z8)WG,'\31^[3,IG^#'\)/W^KOYDEYD>7?14=_^^'O^:A://_^F[>-
M1^KT4WV0S+(+>*S,+B[KYY'YU?<__O#RTV4VRNKH^/#X^V]^_*$]P@8OV73^
MYMWPZ-'SJ#4[F-*K7W_Y\,/+_WYY_MN'U[_^,AS\U\MW[^$?WW]#7]S;RYNK
MN??UC-.\3DM94' <=9GDU;0HY]]%R\4B+<=)E?[MAW?I8I;-EWDZ'/Q4%LM%
MS/-[G8\/[WOMW1/=ZNGJ2Y[%3X^.XT?/CJ+WETD)@Q73Z+R8SXL\>E\7XX];
M.]\MK>=MF1Z\6N:3=!+]*RGA8.LJJHOH[;(<7\*Q1B?QT],G\>DC7>]P\!=?
M\&^PUO*ZS.HLOXC.+LHTG<,W?Y55"),Y6UXLJYK?]"R.3HY.GNSN"O[VPYL4
M/LX_1F^3LL[3LHK>O#G__L=W,/Q_'KX]C'XNRHL$R"D=+_%<4O/].1!D44:O
MLOK?%VF9S"8\M[\G\\5S(,/#W5TU_^_AXRR7$\R \'"D@Z/#$_@4#K&*@&?"
MG8*/DSJ[8F927Z91E5[A8B/> T>QL'/#P2RK:KBL&>S7^#*=+&=I]%H>O$S+
MM"[BW=V3O_TP_J:(^JGA^/3H.#J[2O-EJEMQ-H>'0<#$T>/Z,GHU*XJ2G\4W
M_D]1?HPC_1?,Y^CXV:ZO?AW%GSP]PIWY*/NP<K%/=WVQ7_#Z'A\?12^3JHX>
M/P-">5\#8Z_CZ(DCFOM[DSF,_\%C.#G9Y6-XDTR0OI)\$OT$C&:&XNZ[W9UP
M@UD2 S6Z9=14+>,HB5ZDL^0:E)-H7)2+H@1>6N3#P1ZRC[_/)G\LB^>@L"R2
M_.;O)?VU'T>+LE@454JZ3E95P&]P@ZIT-L-/+ ]>&NX;>>;[_6\_./[[_3>_
M_? Z8NX;V==:SNW>/1R ZAQ=7Q;SZ*981CCO9$S:2%)%94,@V-$:PL(O!CA)
M<@&:S$52$]_T.FK%.FKGG.H4-HF5.AT*?SQFW:Y"W0[V*2FCJV0&^_,?1X?
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M(G,+@3DV3J %U;%B 8^@R!G8V@UN9J^O:D,R;]F!*STXSQO%,E//S^P8MUG
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M*0NG<:9$QE()==2>VX2_N$)_!SXGH?)-F2J>H&^*QWG/.A6%'6S.IN9*36F
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M@1G?,6  Q;"BUQ:QR@MN:*&YB=ZX9T[=*O$L&,>?VSN-TLMD-HU\#O!:O(C
M.T%2D!FAA 4PO#>I7!'G4C?9IE_&T44V1;1<Y'^H6@3^290C\B-R3VCG %]\
MGI$9I]T(;FS0BCLCE]KV&;W]E"LX!3X-8[-W GDW8X^2\C//N%5U ^UHJF&5
M)LRO7]2"*8?RD27I4LK=3+,EUQ?)2P4F$5$\E$9LXI*(%_\+1A,G6>)Q0K4
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M$WN4LB[AYQ*NO4LE<S"QZ+;GH798F'\FNTO3=!NX<A*T?G]P.AR\))0!\GH
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M 568.)!KVSD&(PRNBZ+W>F&_R5R+Y_1W 8!#B-@0CDTP?^'(:P:^42_#%)F
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MX2/61X-1,#=U>!2HR'*"%];R/I'N[29"L21GED'*>$,T=:BD^AF[S41LX0=
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MA9(VV(GES7/CX^^C&&2WR-CPE,0;D=A31&Q#LUUK+F/SGOAI/P\@3E:L#"7
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MCB>O/K[^.Q+ZR:^?W[][^?]02P,$%     @ 05X*70#YQ%FP.0  ? H! !4
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MMEOS*(_&:R!4@#FS&!94SL.R"[PB#ZZR;!J$Z32X#I-5.$YP]+2( 1=I_&Z
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MD.'0/K)9 ]RK %\+B-(ZP,$*8/1P!KA,XTV!HLD$/G(IVM=N&>+G(IEW/V;
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M]:FHXF-"1B^,2VT"QY;$1%Q(&0.HP!$8DX6EHX/,5FB+5 [7LG#H1)-P['!
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M!5M0G_C"BCU#OW";%O@"^"OJ@6+FS\TB-1>K6A05$ZM'+Z!G@E\ZT+Q1%M]
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M,VWF3U_+M/5=XN RN@]R%WU"@S<XS=SJ\896*(-H09:TF&SZTV@,B(=(;'-
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MC>'2WC,NC9/E9I3;B"(D:VW$>S!P^RJE-@?5_N?8V("J@))Q84TJ%H%9E_W
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M1:DC.(T3*O9"E<=<D0P(N,Z%Q4":E2YP<G^PV#ZL:K"GSI\V'0)#)PFYMNY
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M\.SR':WP0^_T?6\TZL&) +CHA=[1WRYA+@U]7/O1X.+\$J;#15^>XO+A89@
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M5#?56(7JH:!-5;7P'J^[%87.4^W%P(QI)R65.[>,RZ@MH.K !L&0]^1N*+%
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M%/R'TC^YP $;+0"$$:6;,Y%C$&T>L)UM[QSXU$)8',R;CIWZ4'Z?**4#=J*
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MJUO6#+-%EO'&^!E/\P_:#Z$J[(H^/<O.P]-]A(!-!0>G0^YU1!60\%F%A<Z
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MM44_._._0Z.?J_T74$L! A0#%     @ 05X*70JDQ@0I P  Y0L  !$
M         ( !     ')E<&PM,C R-C X,#DN>'-D4$L! A0#%     @ 05X*
M7>V%X&K]"@  ?X8  !4              ( !6 ,  ')E<&PM,C R-C X,#E?
M;&%B+GAM;%!+ 0(4 Q0    ( $%>"EU!];1>6P<  -97   5
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8=&U02P4&      @ "  2 @  &RP!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>tm2622673d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="repl-20260809.xsd" xlink:type="simple"/>
    <context id="AsOf2026-08-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737953</identifier>
        </entity>
        <period>
            <startDate>2026-08-09</startDate>
            <endDate>2026-08-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-08-09" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-08-09" id="Fact000004">0001737953</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-08-09" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-08-09" id="Fact000010">2026-08-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-08-09" id="Fact000011">REPLIMUNE GROUP, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-08-09" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-08-09" id="Fact000013">001-38596</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-08-09" id="Fact000014">82-2082553</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-08-09" id="Fact000015">500 Unicorn Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-08-09" id="Fact000016">Suite 303</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-08-09" id="Fact000017">Woburn</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-08-09" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-08-09" id="Fact000019">01801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-08-09" id="Fact000020">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-08-09" id="Fact000021">222-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-08-09" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-08-09" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-08-09" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-08-09" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-08-09" id="Fact000026">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-08-09" id="Fact000027">REPL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-08-09" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-08-09" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
